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Initially, this doctoral thesis had the major and ambiguous aim of gaining a deeper 
knowledge of the genetic and molecular mechanisms that underlie the leukemogenesis process. 
We explored and carried investigations on three types of hematological malignancies. Since the 
work done in two of them has been already published and communicated in meetings, we have 
chosen for this PhD dissertation, and its corresponding public defence, the more scientifically 
challenging project entitled “Biological and functional characterization of the fusion gene NUP98-
HOXA9 in Acute myeloid leukemia: New therapeutic approaches”. A brief description of the 
other two is presented below: 
1. Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with 
t(4;21)(q21;q22) 
(This work was published in Haematologica in April 2012, Appendix II) 
We describe the molecular characterization of a new t(4;21)(q21;q22) in a de novo 
myelodysplastic syndrome that resulted in the deletion of the RUNX1 gene. We demonstrated by 
quantitative real-time RT-PCR an almost complete depletion of the expression of the RUNX1 
gene in our t(4;21) case, compared with CD34 + cells, that was independent of mutation or DNA 
methylation. We explored and confirmed the fact that this abrogation also prevents 
transactivation of RUNX1 target genes, shedding some light into the genetic origin of the 
thrombocytopenia and the myelodysplastic features observed in our patients, and certainly 
mimicking what has been observed in the presence of the RUNX1/ETO fusion protein. 
2. The downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the 
effect of the most frequent IgH translocations observed in the non-hyperdiploid subtype.  
(This work was published in Leukemia in April 2013; Appendix II) 
We compare the micro RNA (miRNA) expression proﬁles of the two big groups of multiple 
myeloma (MM):  non-hyperdiploid (nh-MM) group, highly enriched for IgH translocations, and 
hyperdiploid (h-MM), typically characterized by trisomies of some odd-numbered chromosomes. 
We found that target genes of the most differentially expressed miRNAs are directly involved in 
the pathogenesis of MM; speciﬁcally, the inhibition of hsa-miR-425, hsa-miR-152 and hsa- miR-
24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, 
FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH 
chromosomal translocations occurring in nh-MM. Importantly, we validate these results in 
primary cases of h-MM. These data establish the importance of miRNA deregulation in the 
context of MM, thereby opening up the potential for future therapeutic approaches based on 
this molecular mechanism. 
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RESUMEN 
   La translocación cromosómica t(7;11)(p15;p15), que origina la proteína de fusión NUP98-
HOXA9 (NH), aparece como evento primario en el 1% de los pacientes con Leucemia Mieloide Aguda 
(LMA) y está asociada con una forma muy agresiva de leucemia (mal pronóstico y baja supervivencia 
global). Aunque se ha sugerido un papel como factor de transcripción oncogénico, se desconoce el 
mecanismo molecular mediante el cual NH tiene estos efectos. Además, no existe una terapia 
específica para estos pacientes, que son tratados con regímenes de quimioterapia estándar muy 
ineficaces. Por ello, nuestro objetivo ha sido generar modelos celulares humanos que expresen la 
proteína quimera de forma constitutiva, en los que poder estudiar su papel en la transformación 
leucémica, así como ampliar la búsqueda de nuevas dianas terapéuticas que permitan tratar de 
forma dirigida a pacientes que presentan esta translocación cromosómica. Así, hemos identificado 
por primera vez los sitios de unión al ADN de NH, la mayoría de los cuales son regiones génicas 
potenciadoras que permiten regular la expresión de genes implicados en el desarrollo de la LMA. En 
concreto, hemos demostrado que NH induce directamente la sobreexpresión del complejo MEIS1-
HOXA9-PBX3, un elemento clave en la biología de leucemias originadas por otros reordenamientos 
cromosómicos. Para confirmar la importancia de este complejo también en este tipo de LMA, 
demostramos que el péptido HXR9, un inhibidor de la interacción HOXA9-PBX3, es capaz de matar 
selectivamente a las células que expresan NH. Además, observamos que, tanto en un modelo celular 
humano que expresa NH generado a partir de progenitores hematopoyéticos (hHP-NH) como en 
pacientes con la translocación cromosómica, la proteína de fusión es capaz de activar y reprimir la 
expresión de sus genes diana. De hecho, demostramos que la interacción de NH con p300 (un 
activador transcripcional) y con HDAC1 (un inhibidor transcripcional) puede explicar este papel 
activador-represor de la proteína de fusión. Apoyando esta hipótesis, encontramos un efecto 
inhibitorio dramático de la viabilidad de hHP-NH con el tratamiento con LBH589, un inhibidor de 
HDACs, lo que nos lleva a considerar su potencial terapéutico en esta leucemia. Finalmente, en un 
intento de comprender la contribución de las dos partes que forman la proteína de fusión en la 
regulación de la expresión génica, observamos que un tercio de los genes diana de NH son comunes a 
HOXA9. Así mismo, de forma sorprendente, hemos descubierto que también NUP98 parecía 
funcionar como un factor de transcripción implicado en la regulación de la hematopoiesis. El nuevo 
papel descubierto para esta nucleoporina ayudará a comprender mejor cómo funciona NH, así como 
otras fusiones leucémicas en las que también interviene NUP98. En resumen, estos resultados nos 
han permitido identificar algunos de los mecanismos patogénicos más relevantes inducidos por NH e 
identificar nuevas dianas terapéuticas que han sido estudiadas en los modelos celulares, con 
resultados muy prometedores.  
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ABSTRACT 
The chromosomal translocation t(7;11)(p15, p15), which results in the oncogenic fusion protein 
NUP98-HOXA9 (NH), is a rare but recurrent oncogenic event in AML that is associated with very poor 
prognosis and short overall survival. The molecular processes triggered by NH are poorly understood, 
even though a potential role as an aberrant transcription factor has been proposed. Moreover, there 
is no specific therapy for these patients; they are treated with ineffective standard chemotherapy 
regimens. Therefore, our main objective has been to generate human cellular models that 
constitutively express the chimera protein, to study its role in leukemic transformation and expand 
the search for new therapeutic targets that enable the treatment of the patients with this 
chromosomal translocation in a targeted manner. Using these models, we have described for the first 
time the DNA binding sites of NH, most of which are enhancers that regulate the expression of genes 
involved in the development of AML. In particular, we have shown that the direct overexpression of 
the complex MEIS1-HOXA9-PBX3, a key element in the onset of leukemia that is driven by other 
chromosome rearrangements in AML, is also one of the actionable pathogenic mechanisms induced 
by NH. We have demonstrated that the peptide HXR9, an inhibitor of the interaction HOXA9-PBX3, 
was indeed able of selectively kill cells expressing NH. Furthermore, we have observed that, in a 
model of human hematopoietic progenitors expressing NH, and also in patients with the 
chromosomal translocation, the fusion protein was able to activate and repress the expression of 
their target genes. We have also shown that the interaction of NH with p300 (transcriptional 
activator) and HDAC1 (transcriptional inhibitor), could explain this activator-repressor role of the 
fusion protein. Supporting this hypothesis, we have found a dramatic inhibitory effect on hHP-NH 
viability after the treatment with LBH589 (an HDAC inhibitor) which allowed us to consider its 
therapeutic potential for patients carrying the translocation. Finally, in an attempt to understand the 
contribution of each of the two NH moieties to the regulation of gene expression, we found that a 
third of the target genes of NH are common to HOXA9 wt. In addition, ChIP-seq results for NUP98 wt 
revealed the potential role of this nucleoporin in regulating hematopoietic differentiation. This newly 
role of NUP98 is likely to contribute to a better understanding of how NH, as well as other leukemic 
fusion proteins in which NUP98 is involved, works.  
To summarize, these results have allowed us to characterize some of the most relevant 
pathogenic mechanisms induced by NH and to identify new therapeutic targets that have been 
studied in our model, yielding very promising results.  
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Ac  - Acetylation  
AES  - Amino-terminal Enhancer of Split protein 
AML  - Acute Myeloid Leukemia 
ANWL  - Ala-Asn-Trp-Leu motif 
APL - acute promyelocytic leukemia 
Ara-C  - Cytarabine (arabinofuranosyl cytidin) 
AUL - acute undifferentiated leukemia 
B-ALL - B-cell acute lymphoblastic leukemia 
BFU-E  - Burst Forming Unit-erythroid 
CA-AML  - Cytogenetically abnormal AML 
CBF  - Core binding factor 
CFU  - Colony Forming Unit 
CFU-G  - Colony Forming Unit-granulocyte 
CFU-GEMM  - Colony Forming Unit-granulocyte, erythrocyte, macrophage, megakaryocyte) 
CFU-GM  - Colony Forming Unit-granulocyte, macrophage 
CFU-M  - Colony Forming Unit-macrophage 
ChIP  - Chromatin Immunoprecipitation 
ChIP-seq  - Chromatin Immunoprecipitation Sequencing 
CML  - Chronic Myeloid Leukemia 
CML-BC - chronic myelogenous leukemia in blast crisis  
Co-IP  - Co-immunoprecipitation 
CR  - Complete Remission 
eRNA  - Enhancer RNA 
FDA  - US Food and Drug Administration 
FDR  - False Discovery Rate 
FG repeats  - Phe-X-Phe-Gly or Gly-Leu-Phe- Gly amino acid residues 
GBD  - GLEBS binding domain 
GLEBS  - Gle2-binding sequence 
GLFG  - Gly-Leu-Phe- Gly 
GSEA  - Gene Set Enrichment Analysis 
H3  - Histone 3 
HATs  - Histone acetyltransferases 
HD  - Homeodomain 
HDACi  - HDAC inhibitor 
HDACs  - Histone deacetylases 
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hHP  - Human Hematopoietic Progenitor 
IPA  - Ingenuity Pathways Analysis 
K  - Lysine 
LC50  - Median Lethal Dose 
LOH  - Loss of Heterozygosity 
MD  - MEIS domain 
MDS  - Myelodysplastic Syndrome 
Me  - methylation 
NH  - NUP98-HOXA9 
NPC  - Nuclear Pore Complex 
Ph  - Philadelphia Chromosome 
PM  - PBX motif 
PolII  - Polymerase II 
qPCR  - Quantitative PCR 
R9  - 9 Arginine residues 
RBD  - RNA binding domain 
T-ALL  - T-cell Acute Lymphoblastic Leukemia 
t-AML - therapy-related acute myeloid leukemia 
t-MDS - therapy-related myelodysplastic syndrome 
TSS  - Transcription Start Site 
WBC  - White Blood Count 
 wt  - Wild Type 
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1 ACUTE MYELOID LEUKEMIA 
Acute Myeloid Leukemia (AML) is a highly malignant hematopoietic tumor that is 
characterized by the uncontrolled proliferation, increased survival and impaired differentiation 
of the hematopoietic myeloid progenitor cells. These abnormal immature leukemic cells, known 
as blasts, accumulate in blood and bone marrow. The presence of 20% or more of blasts in bone 
marrow is the main criteria for the diagnosis of AML1. This causes the disruption of normal 
hematopoiesis, which results in fatigue, infection, bleeding and multiorgan failure2.  (Figure 1A 
and 1B) 
AML represents approximately 25% of all leukemia diagnosed in adults with a median age 
range that goes from 66 to 71 years3. On average, the age-standardized incidence rate for AML is 
2.95 cases per 100 000 in Europe, and 4.6 cases in USA. However, the most worrying aspect of 
this disease is its high mortality rate, with a 5-year Overall Survival (OS) rate of 40% to 45% (OS in 
older patients still remains poor at < 10% after 5 years)4. Thus, almost 70% of patients on 
average succumb to the disease, representing more than 9,000 deaths each year alone in the 
United States5.  
           
 
 
 
Figure 1: Cellular origin of Acute Myeloid Leukemia (A) Shows the differentiation of normal lymphoid and 
myeloid lineage from hematopoietic stem cells. Yellow arrow points at the abnormal undifferentiated leukemic blast 
cells. (Modified from How stem cells work by Stephanie Watson) (B) Shows how in AML, the normal hematopoietic 
balance between proliferation and differentiation is disrupted and an increase in proliferation with a blockage of 
differentiation is observed. 
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1.1 Genetic origin and evolution of AML 
The production of blood is a tightly controlled process in which transcription factors and 
chromatin remodeling genes are necessary for the orchestrated regulation of gene expression 
that defines the phenotype of a given blood cell6.  
 
1.1.1 The “Two hits hypothesis” 
For many years, the accepted model of leukemogenesis was the “two hit hypothesis”. This 
model suggests that mutations of a single gene are rarely sufficient to cause the development of 
AML and that instead, two different types of genetic mutation are required for malignant 
transformation of a myeloid precursor: Class I and class II. Class I mutations lead to increased 
proliferation, survival, or evasion of apoptosis, and include mutations conferring constitutive 
activity to tyrosine kinases or deregulation of downstream signaling molecules, such as BCR-ABL 
or mutations in FLT-3, c-KIT, and RAS. Class II mutations impair differentiation or enhance self-
renewal of hematopoietic progenitors and include the translocations associated with the core-
binding factor (CBF) or mutations in genes that are involved in transcriptional regulation, such as 
p300, CBP, MOX, TIF2, and MLL7,8. However, recent research highlighting the presence of novel 
mutations in genes that are related to epigenetic control of the genome and modifications to the 
epigenome itself found in the AML patients suggests that Class I and Class II mutations are only 
one part of a more complex picture. Furthermore, that some other mutations occurring in AML 
are not regarded as belonging to Class I or Class II also indicates that the “two-hit” theory is an 
oversimplification9. Moreover, there is evidence that there is also a temporal component to 
leukemogenesis: mutations have to occur at a particular point in cell development, and in a 
particular order, to allow for leukemic transformation7. Therefore, the models for the 
development of AML are becoming increasingly complex.  
 
1.1.2  New model for AML development 
An example of a model that best fits the actual scenario of AML would be the one proposed 
by Welch et al10 (Figure 2). In the first step of the leukemogenesis, a driver mutation (recurrent 
mutations with translational consequences or recurrent chromosomal translocations that result 
in leukemic fusion genes) occurs within the context of a Human Hematopoietic Progenitor (hHP) 
that already contains hundreds of random benign mutations that have accumulated over time. 
This mutation confers a proliferative advantage to the cell, allowing the formation of a clone that 
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expands, carrying along all of the random background mutations within its genome (passengers). 
Eventually, an additional driver mutation (cooperating mutation) occurs within a cell in an 
expanding clone and it becomes the leukemic “founding” clone that is detected at the diagnosis. 
Thus, these cells contain only a few drivers but many passengers. Each progression event yields a 
small cluster of new mutations, of which only one or two may be relevant for clonal or subclonal 
outgrowth.  
In summary, the development of AML is associated with an accumulation of acquired genetic 
alterations and epigenetic changes in hematopoietic progenitor cells that alter the normal 
cellular mechanisms. AML constitutes an exceptional biological model of cooperative effects 
between genetic and epigenetic alterations on the transformation, progression and phenotype of 
a clonal neoplasia11. 
 
Figure 2: Integrated model for the origin and evolution of the oncogenic events in AML. Hematopoietic 
progenitors (hHP, shown in green) are long-lived cells that accumulate random benign background mutations as a 
function of age (X). The initiating mutations, which are drivers, provide an advantage for the affected cell and clonal 
expansion (shown in yellow). Likewise, 1–5 of cooperating mutations (Y) contribute to progression in most cases of 
AML, giving the expanding clone an additional advantage. Clonal outgrowth of cells with appropriate progression 
events results in AML, which is dominated by the “founding” AML clone, depicted in red. Subclones arise from the 
founding AML clone by acquiring a small number of additional mutations that confer an advantage to that cell, along 
with any additional background mutations (Z) that may have occurred in the interim. Therefore, X represents the 
age-dependent passenger mutations pre-existing in HSPC; Y, the passenger mutations gained between initiating and 
cooperating mutations; and Z, the passenger mutations gained during progression to subclone  (Modified from 
Welch et al., Cell, 2012). 
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1.2 AML prognostic factors 
Although there are unifying cellular characteristics, AML remains a heterogeneous group of 
diseases in terms of clinical presentation, genetic alterations, prognosis and response to 
treatment. Classifying the different types of AML and especially identifying prognostic factors in 
this disease remains one of the main needs for the clinicians nowadays. 
Prognostic factors may be subdivided into those related to patient characteristics and 
general health condition and those related to characteristics particular to the AML clone. Patient-
related factors include age, as a clear adverse prognostic factor, and comorbidities, as an 
important aspect to be evaluated before the treatment of the patient. The AML-related factors 
are the white blood count (WBC), existence of prior myelodysplastic syndrome (MDS), previous 
cytotoxic therapy for another disorder and cytogenetic and molecular genetic changes in the 
leukemic cells at diagnosis. Other factors have been also included in this group, but the 
prognostic effect is observed with variable consistency among studies12.  
Numerous recurrent cytogenetic aberrations have been identiﬁed in AML cases that are not 
only diagnostic markers for speciﬁc subtypes but also constitute independent prognostic factors 
for response to therapy and for overall survival5,11 In particular, recurrent chromosomal 
rearrangements that result in the production of fusion proteins are common initiation events in 
40% of AML cases13.  The European LeukemiaNet has proposed a standardized reporting system 
that correlates genetic abnormalities with clinical outcome, including data from cytogenetic 
analysis and from mutation analysis of NPM1, CEBPA and FLT3 genes.(Table 1) This classification 
divides AML patients into 4 risk groups with a high variability between them (e.g. complete 
remission observed in 80-90% of the patients in the favorable genetic group but only in 30% of 
the patients in the adverse group4). 
Different next-generation sequencing analysis of AML genomes has recently shown 
hundreds of separate genetic lesions within individual cases, which represents an important 
advance in the study of this disease14. Moreover, the progress in genomics technology has 
proven valuable for the discovery of novel leukemia subgroups and prognostic signatures. 
However, to date, conventional cytogenetics analysis is a mandatory, irreplaceable and the 
strongest component in the diagnosis and prognosis evaluation of a patient with suspected 
AML12. 
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Table 1: Standardized correlation of cytogenetic and molecular genetic data with prognosis data in 
AML (Modified from Döhner et al12) 
GENETIC GROUP SUBSETS 
Favorable 
t(8;21(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBF-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
All AMLs with normal karyotype except those included in favorable group 
Intermediate II 
t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged  
-5 or del(5q); -7; abnl(17p); complex karyotype 
 
1.3 Treatment 
1.3.1  Standard chemotherapy protocols 
 
1.3.1.1 Intensive induction therapy 
Patients diagnosed with AML, considered suitable for intensive chemotherapy, are treated 
with a combination of 3 days of anthracycline and 7 days of cytarabine (“3 + 7”)4,12. Anthracycline 
(eg. Idarubicin) inserts itself into the DNA and prevents that DNA from unwinding by interfering 
with the enzyme topoisomerase II15. Cytarabine (arabinofuranosyl cytidin or ara-C) is a 
pyrimidine nucleoside analogue that inhibits the synthesis of DNA, by blocking DNA 
polymerase16. Complete remission (CR) can be achieved in 65% to 75% of younger patients (≤ 60 
years) and in approximately 40% to 60% of older patients (> 60 years). 
For AML patients who could not tolerate the intensive treatment, the therapeutic options 
are reduced and include best supportive care with hydroxyurea, low-dose cytarabine and 
hypomethylating agents such as decitabine or azacitidine. CR can be achieved in 10% to 30% of 
patients treated with this low-dose therapy4. 
 
1.3.1.2 Consolidation phase 
In patients who achieve a CR after induction chemotherapy, some post-remission therapy is 
required to prevent relapse. This treatment is based on genetic and molecular features and can 
range from high-dose cytarabine to allogeneic hematopoietic stem cell transplantation4,12.  
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The risk of relapse following consolidation phase is highly variable among the different 
prognostic groups of AML, but remains high for all cases (≈ 30% in the favorable group)17. Indeed, 
in the majority of patients with AML who achieve CR, the leukemia will recur within 3 years after 
diagnosis. In general, the prognosis of patients after relapse is poor and treatment options are 
unsatisfactory. Therefore, this scenario raises the urgent need for improved therapies for the 
disease. 
1.3.2 Future perspectives  
 
The association of specific cytogenetic subtypes of AML with altered molecular pathways has 
led to the introduction of specifically targeted therapeutics (e.g. retinoic acid in PML-RARA 
positive cases or selective FLT3 inhibitors in cases with FLT3 internal tandem duplication). 
However, these discoveries have not translated into significant advancements in survival for the 
majority of patients with AML that are still treated with the current standard chemotherapy 
regimens and most of them ultimately relapse17. Therefore, the identification of novel 
therapeutic targets for the treatment of this disease is of great importance. For this reason, it is 
necessary to understand completely the underlying biology for each subtype and explore 
whether the leukemic transformation could be mediated by common or overlapping genetic 
programs downstream5. Identifying genetic pathways that cooperate in the leukemogenesis will 
facilitate the understanding of the molecular mechanisms at play and the search for common 
critical therapeutic targets. 
1.3.2.1 HDAC inhibitors: 
It has been demonstrated that the epigenetic regulation of gene expression is crucial to the 
onset and progression of cancer. Changes in the structure of nucleosomes have a direct effect in 
the remodeling of chromatin between relatively “open” and “closed” forms that allow or prevent 
gene expression. Histones, the main structural component of the nucleosomes, belong to the 
diverse group of proteins regulated by acetylation, a common and reversible epigenetic 
modification18. Acetylation is regulated by the opposing activities of histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). HATs transfer acetyl groups to amino-terminal lysine 
residues in histones, which results in a local chromatin expansion and an increased accessibility 
of transcription factors to DNA, whereas HDACs catalyze the removal of acetyl groups, leading to 
chromatin condensation and transcriptional repression19.  
Altered acetylation of histone proteins has been identified as a hallmark of cancer 
development20 and several studies have widely shown that HDACs are promising targets for 
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therapeutic interventions intended to reverse aberrant epigenetics states associated with 
cancer. Indeed, HDAC inhibitors (HDACi), a novel class of chemotherapeutic agents, have been 
found to have anticancer activities with remarkable tumor specificity in hematological 
malignancies. Some HDACi have been already approved by the US Food and Drug Administration 
(FDA), such as varionstat or romidepsin, for the treatment of cutaneous T-cell lymphoma21,22. 
Others such as Panobinostat (LB589), a potent oral pan-HDACi in Phase I/II clinical trial, holds 
promise as a combination therapy for a broad range of cytopenias, including some subtypes of 
AML18.  
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2 NUP98-HOXA9 FUSION PROTEIN 
The chromosomal translocation t(7;11)(p15;p15), that results in the oncogenic fusion protein 
NUP98-HOXA9, was first described in 197623, but it was not until 1996 when the genes involved 
in the rearrangement were identified24 (Figure 3). It is a rare but recurrent event that occurs 
predominantly in patients with de novo AML. It must be noted that it has also been observed in 
some cases with trilineage myelodisplasic syndrome (MDS) and chronic myelomonocytic 
leukemia25,26. In some occasions it appears in a secondary leukemia after an exposure to 
Topoisomerase II inhibitors27.  It is associated with a very poor prognosis and a low degree of 
overall survival14.  It appears more frequently in Asian countries, in females and in younger 
people, compared to the other M2-subtype cases. Moreover, the patients are highly refractory 
to intensive treatment, including allogeneic stem cell transplantation14. Because of such special 
features that characterize the patients with this chromosomal translocation, it has been 
considered as an independent entity14. However, despite the large severity of the leukemia 
induced by this translocation, the oncogenic events underlying its malignancy are poorly 
understood. 
 
Figure 3: t(7;11)(p15;p15) chromosomal translocation. Normal and derivative chromosomes that result 
from the translocation. 
 
2.1 Genes involved in the fusion protein 
 
2.1.1 NUP98 
The 98 kDa nucleoporin (NUP98) is a component of the Nuclear Pore Complex (NPC), a large 
route of transport between the nucleus and the cytoplasm, allowing small ions and polypeptides 
to pass through by diffusion and larger macromolecules (mRNA and proteins > 40 kDa) by 
multiprotein structure embedded in and traversing the nuclear membrane. It consists of 
approximately 30 different proteins, many of which are present in multiple copies, arranged in a 
distinguishing octagonal symmetry around a central transport channel28. The NPC provides a 
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bidirectional active transport mediated via carrier proteins and transport factors collectively 
called karyopherins (e.g. importins, exportins, and transportin)8. A still small but accumulating 
body of data suggests that these structures and, in particular, Nup proteins exposed to the 
nucleoplasmic face of the NPC, also play important roles in modulating chromatin structure and 
gene expression28-30. 
The NUP98 gene maps to chromosome 11p15.4, is 122 kb long and is located 3.6 Mb from 
the telomere on the short arm of chromosome 11. It is composed of 33 exons and encodes 2 
alternatively spliced mRNA variants: NUP98 and NUP98-NUP96. NUP98 splice variant includes 
only the NUP98 portion of the NUP98-96 mRNA and its expression is very low compared to the 
other variant. NUP98-NUP96 precursor polypeptide undergoes autoproteolysis and is cleaved 
into two peptides: NUP98 and NUP96 8. This coexpression from the same mRNA and its 
subsequent cleavage promotes and regulates the correct localization of the two mature peptides 
to the NPC. However, two pools of NUP98 have been found: an NPC-bound fraction (on both the 
nucleoplasmic and cytoplasmic domains) and an off-pore intranuclear fraction31 (Figure 4). 
Phosphorylation of NUP98 during mitosis causes it to release from the pore and it is possible that 
this post-translational modification could promote NUP98 cycling to and from the NPC.31,32 
 
 
 
Figure 4: The nuclear pore complex (NPC). The core structure of the NPC is maintained by the NUP93-205 
complex (black) and the supporting structures of the NUP107-160 complex (grey) on the nuclear and cytoplasmic 
faces of the pore. The cytoplasmic filaments (blue) and the nuclear basket (black) allow the pore to sense the 
cytoplasmic and nuclear compartments, respectively, and regulate transport of macromolecules through the NPC via 
binding sites on FG Nups in the barrel of the pore. The entire pore is anchored to the nuclear envelope by protein–
protein contacts between transmembrane Nups, T.M. Nups (pink) and the NPC scaffold. NUP98 is found on the 
nuclear and cytoplasmic faces of the pore (red) as well as in the nucleoplasm. (Modified from Franks et al., Trends in 
Cell Biology, 2013) 
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Approximately a third of all nucleoporin proteins contain repeats of Phe-X-Phe-Gly amino 
acid residues, or Gly-Leu-Phe-Gly (GLFG) residues, collectively called FG repeats. However, 
NUP98 is distinct from other FG nucleoporins because it contains multiple nontandem GLFG 
repeats8. The GLFG repeats are thought to function as docking sites for different proteins. They 
have been shown to bind nuclear exportin 1 protein CRM1 (XPO1) and the mRNA export factor 
TAP, among others. The nontandem FG repeats of NUP98 are intersected by a coiled-coil 
domain, the Gle2-binding sequence (GLEBS) motif in the N-terminal portion of NUP98 that 
interacts with the RNA export factor RAE1 (Gle2). Finally, the C-terminal end of NUP98 contains 
an RNA-binding motif that is also involved in the export of mature forms of RNA8 (Figure 5).  
There is evidence that NUP98 is involved in RNA export and protein import33.  
 
 
Figure 5: Schematic representation of the NUP98 protein. Red lines indicate GLFG repeats, red box 
indicates the Gle2-binding domain (GBD), purple box indicates the RNA-binding domain (RBD) and the green lines 
represents the autoproteolytic cleavage site. Known NUP98 interacting proteins are indicated: CBP/p300 (blue), TAP 
(yellow), RAE (green) and HDAC1 (purple) (Modified from Gough et al., Blood, 2011) 
 
In addition to its well established role in mediating nucleo-cytoplasmic transport, recent 
studies have shown that the intranuclear fraction of NUP98 could also localize to promoters of 
multiple genes28-30,34. Moreover, the downregulation of different target genes after the 
knockdown of NUP98 suggestes that it could have important functions as a transcription factor in 
Drosophila30,34. Supporting these findings, it was found that the FG repeat region of NUP98 is 
able to recruit p300 to activate transcription or HDAC1 to repress transcription33 (Figure 5). Later, 
Liang et al35 demonstrated that NUP98 dynamically associates with the human genome in a 
manner that is tightly linked to differentiation status and developmental gene expression. They 
found that in human progenitor cells NUP98 is highly associated to active genes and that it is 
functionally important for their expression. However, in differentiated cells, NUP98 mainly 
interacts with silent chromatin domains. Importantly, it seems that both the intranuclear and the 
NPC-bound fraction of NUP98 are involved in the developmental gene regulation. Although the 
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mechanisms by which this nucleoporin is targeted to chromatin remain unclear, it is known that 
at least part of its DNA binding activity resides in the FG repeat region33. 
Finally, FG repeats also allow NUP98 to interact with the dynein light chain, DYNLT1, which 
suggests a role of NUP98 in the process of chromosome segregation36. 
Frequent allelic loss at the 11p locus has been reported in AML and indeed, Loss of 
Heterozygosity (LOH) of the NUP98 gene has been considered an adverse prognostic factor in 
Acute Myeloid Leukemia (AML)37. However, the molecular mechanisms involving NUP98 gene 
locus and its function in leukemogenesis are still unknown.  
 
2.1.2 HOXA9 
 
Homeobox A9 (HOXA9) is a member of the highly conserved HOX protein family of 
transcription factors, which play key roles in both development and hematopiesis38.  
In mammals, 39 genes have been identified, separated into four clusters (A-D) located in 
four different chromosomes. HOX genes are numbered such that genes of different clusters with 
the same number have greatest similarity and functional redundancy (paralogs). (Figure 6) 
 
 
 
Figure 6: Clustered HOX genes. Schematic structure of HOX genes clusters. The 39 HOX genes are located on four 
different chromosomes. Human HOX genes are shown by colors and blank spaces shown missing genes. (Modified 
from Alharbi et al, Leukemia, 2013) 
 
In particular, the HOXA9 gene is located in chromosome 7p15, is 7.8 kb long and is 
composed by two exons. 
HOX proteins bind to DNA through a homeodomain (HD), which is found in the C-terminus of 
the protein. The HD is highly conserved between HOX proteins and includes conserved tyrosine 
residues which may regulate HOX activity. However, this regulation may be different for each 
type of HOX protein. For example, the HD-tyrosine phosphorylation of HOXA9 increases the 
binding affinity to its target genes whereas the affinity of HOXA10 to the same genes is 
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decreased.39,40  HOX proteins need cofactor interactions in order to increase the selectivity, 
affinity and specificity for their DNA-binding sites. The most important cofactors are pre-B-cell 
leukemia (PBX) and myeloid ectopic insertion site (MEIS) families. Indeed, HOX proteins harbor 
specific binding domains for this cofactors:  PBX motif (PM) and MEIS domain (MD).41 
Additionally, HOX-PBX binding requires a hexapeptide motif containing a critical tryptophan 
residue in the HOX proteins42. (Figure 7) 
 
 
 
Figure 7: Schematic representation of the HOXA9 protein. Green box represents MEIS domain (MD), 
pink box corresponds to PBX motif (PM), purple box represents the hexapeptide (H) and yellow box would be the 
homeodomain (HD). 
 
HOX gene transcription during hematopoiesis is tightly regulated in a temporal manner. 
Maximal expression of HOX1–6 occurs in most primitive hematopoietic stem cells (CD34+CD38−) 
in humans, with downregulation of these genes during CD38+ differentiation. Subsequently, 
HOX7–11 expression is maximal during commitment (CD34+CD38+) with downregulation as 
differentiation proceeds43. Indeed, the expression of HOX genes is almost absent in CD34− cells, 
which are considered differentiated bone marrow cells. Interestingly, the different HOX clusters 
also have specific patterns of lineage-restricted expression: HOXA genes are expressed in 
myeloid cells, HOXB genes in erythroid cells and HOXC genes in lymphoid cells. HOXD genes are 
not expressed in hematopoiesis despite having similar regulatory regions to the other clusters 41. 
The function of HOX proteins in normal hematopoiesis and leukemia has been widely 
studied. In particular, HOXA9 is required for the maintenance of hematopoietic progenitor status 
and promotes proliferation. Its overexpression in murine bone marrow induces myeloid 
progenitor expansion and, after a very long latency, leads to leukemia. Interestingly, HOXA9 
overexpression only results in a partial inhibition of pre-B-cell differentiation and does not affect 
T-cell development.44 Thus, it has been hypothesized that HOXA9 is involved in the selection of 
myeloid versus lymphoid lineage commitment.43 On the other hand, HOXA9-/- mice showed 
deficiencies in myeloid and lymphoid cells with a significant defect in their repopulating ability, 
as well as the corresponding reduction in spleen cellularity and size45. 
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HOXA9 expression is controlled by different transcriptional activators such as MLL and 
caudal-type HOX transcription factor family (CDX1, CDX2 and CDX4). Also, as HOX genes are 
distributed in clusters, they are especially sensitive to changes in the chromosomal 
organization41.  
HOXA9 regulates transcription by interacting with enhancers. Recent genome-wide studies 
have made it possible to identify some potential target genes that are directly related to cell 
proliferation and survival. Most of them are upregulated (MEIS1, different members of HOX 
family, SOX4, CAMK2D, FOXP1, PIM1, EVI1, etc.) but HOXA9 is also able to downregulate some 
targets like RUNX genes46. 
HOXA9 may also bind DNA as heterodimer with MEIS1 or PBX proteins or as a heterotrimer 
with both of them to regulate different genes. Among the targets of these transcriptional 
activator complexes we found the MYB, MEF2C or FLT3 genes.  Notably, the coexpression of 
HOXA9 and MEIS1 in mice significantly reduces the time of latency in the induction of AML and 
there is increasing evidence of the importance that these factors appear to have in the 
development of AML47. Different studies have identified the consensus binding site for HOXA9 
complexes. PBX-HOXA9 would bind to ATGATTTACGAC sequence, MEIS1-HOXA9 consensus 
target would be TGACAGTTAT/C and PBX-MEIS binds to TGATTGACAG. PBX consensus binding 
sites are not underlined, HOXA9 consensus binding sites are underlined and MEIS consensus 
binding sites are broken underlined. Surprisingly, a DNA binding site specific for the MEIS1-
HOXA9-PBX heterotrimer has not been detected but it seems to be interacting with PBX-HOXA9 
consensus sites. Hence, MEIS1 could bind to a PBX-HOXA9 dimer bound to DNA without 
interacting to its specific recognition site. Indeed, MEIS1 enhances in vitro HOXA9-PBX protein 
complex formation48.  
It is therefore unsurprising that the overexpression of HOXA9 is a highly frequent event in 
AML. Its deregulation is associated in some cases with chromosomal rearrangements that involve 
HOXA9 upstream regulators, such as MLL, but also with specific mutations, like NPM1 
mutations41. NPM1 mutations are the most common genetic aberration in AML, reported in 
about 35% of adult patients. Such mutations induce the recolocation of NPM1 into the 
cytoplasm, which leads to the overexpression of HOXA9 and other HOX genes49. 
HOX genes expression has become an important prognostic factor in AML41. In particular, 
HOXA9 has been the single gene correlated with the worst outcome and relapse of disease and 
short survival, among all the genes investigated in AML patients50. Subsequently, low HOXA9 
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expression, as well as low expression of MEIS1, were favorable predictors for AML patient 
outcome and good response to therapy41.  
2.2 Molecular description  
NUP98-HOXA9, the fusion gene originated by the chromosomal translocation, encodes the 
FG repeat-rich portion of the nucleoporin NUP98, fused to the homeodomain region and PBX 
heterodimerization domain of HOXA9 (Figure 8).  
 
 
 
Figure 8: Schematic representation of NUP98, HOXA9 and NUP98-HOXA9 proteins. Arrows indicate 
the breakpoints that originate the chromosomal translocation 
 
Different studies have described four types of fusion sequences in patients with 
t(7;11)(p15;p15), which appeared to be the result of the alternative splicing of NUP98 and 
HOXA914. All of them are in-frame and originate fusion proteins with a similar number of amino 
acids (Table 2 and figure 9). Although it has not been analysed experimentally, it is expected that 
the different fusions act similarly as they retain the same functional domains. Leukemic cells 
from these patients contain at least two different fusion products, but Type I (fusion between 
NUP98 exon 12 and HOXA9 exon 1b) is present in all the patients.  
NUP98-HOXA9 fusion gene Type I has 13 exons and originates a chimeric protein with 579 
aminoacids and 60kDa of molecular weight. 
 
Table 2: Types of NUP98-HOXA9 transcripts 
FUSION TYPE BREAKPOINT 
Nº OF 
NUCLEOTIDES 
Nº OF AMINOACID 
Type I NUP98 exon 12 – HOXA9 exon 1b 1737  579  
Type II NUP98 exon 12 – HOXA9 exon 2 1647  549 
Type III NUP98 exon 11 – HOXA9 exon 1b 1596  532 
Type IV NUP98 exon 11 – HOXA9 exon 2 1506  502 
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Figure 9: Fusion point sequence in each type of transcript. The corresponding amino acids are 
listed below the nucleotide sequence. Black lines represent the breakpoints. (Modified from Chou et a.l, 
Leukemia, 2009) 
 
2.3 Subcellular localization 
NUP98-HOXA9 is located almost exclusively in the nucleus and it is never found, neither as a 
part of nor associated with the NPC. Interestingly, during mitosis, the fusion protein is 
concentrated at kinetochores and along chromosome arms51, unlike NUP98 wt, which is 
distributed throughout the cell.  This association is detected in prophase and persists through 
metaphase and anaphase (Figure 10). Importantly, these novel intranuclear localizations of NH 
require both the GLFG repeats of NUP98 and the homeodomain of the HOX protein. 
 
               
 
Figure 10: Subcellular localization of NUP98-HOXA9. GFP-Nup98 fusions were highly concentrated on 
chromosomes during mitosis and exhibit a punctate staining pattern along mitotic chromosomes.  (Modified from S. 
Xu et al., Molecular Biology of the Cell, 2010) 
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2.4 Mechanism of action   
NUP98-HOXA9 is an oncogenic fusion protein that in murine bone marrow results in a rapid, 
polyclonal myeloproliferative disease progressing to AML by 7-8 months26. However, in human 
primary hematopoietic cells, NH induces long-term proliferation, blocks the differentiation and 
dramatically increases the number of primitive cells, but additional genetic changes are required 
for the progression to the overt leukemia 52,53.   
Specifically, enforced expression of NH in hHP confers a proliferative advantage and 
increases self-renewal. It also alters differentiation by inhibiting erythropoiesis, delaying 
neutrophil maturation and blocking myeloid colony formation54.  
It has been commonly accepted that NH acts as an oncogenic transcription factor53-55. Indeed, 
some studies have analyzed changes in the expression profile in presence of NUP98-HOXA9 in 
hHP and extensive changes with a preponderance of upregulated genes have been detected53-56. 
Among the deregulated genes we can find oncogenes, transcription factors, growth factors, cell 
cycle regulators, tumor suppressors and factors involved in hematopoietic differentiation53. 
However, it has not been determined whether these genes are directly regulated by the chimera 
or their overexpression is a downstream effect.  Based on the involvement of HOXA9 in 
leukemogenesis and its function as transcription factor, it was accepted that the homeodomain 
of HOXA9 conferred NUP98-HOXA9 the ability to bind to DNA to regulate gene expression52. 
However, there are evidences that suggest that NH also induces oncogenic mechanisms beyond 
those mediated by the homeodomain. On one hand, NH induces a leukemia that is preceded by a 
myeloproliferative phase, whereas the leukemia caused by overexpression of HOXA9 is not 
preceded by myeloproliferation25. On the other hand, mutations in the homeodomain do not 
abolish most of the effects of NH on hematopoietic differentiation52. Thus, it seems clear that the 
NUP98 region of the fusion protein is required for the induction of the leukemic transformation 
driven by NH. However, the specific role of NUP98 and how such a broad range of different 
partners can bring similar AML phenotypes is still not clear. NUP98 could be mediating the 
interaction with other proteins through the FG-repeat domain and it has been suggested that 
NUP98-HOXA9 could interact with p30055,57 (transcriptional activator), HDACs37(transcriptional 
inhibitor), CRM158,59 (protein involved in nuclear transport) or AES60 (transcriptional Regulator of 
the TLE family), but limited information is available regarding the features, architecture or the 
effects in leukemogenesis of these interactions. Interestingly, during interphase, there are 
dynamic interactions between NH and endogenous NUP98 that lead to mislocalization of the 
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intranuclear fraction of NUP98, but do not alter the level of NUP98 at the nuclear pore complex. 
During mitosis, this interaction would be disrupted51. In addition, it has been suggested that the 
interaction of NH with DYNLT1 could cause defective chromosomal segregation, contributing to 
the oncogenic transformation36.  
Importantly, recent studies that propose a role for NUP98 in transcriptional regulation30,35 
uncover a very interesting aspect for the study of NUP98 leukemic fusions that must be explored. 
NUP98, together with its ability to interact with different proteins, could allow NH to regulate the 
expression of different target genes. 
Therefore, there is still a long way to completely elucidate the functional contribution of 
each of the moieties of this chimeric protein. 
 
2.5 Cooperating oncogenic events and mutations 
It is accepted that NUP98-HOXA9 fusion gene is a class II mutation, because most of the 
described collaborating events are class I proliferation and survival mutations. However, this 
would be another example of how simplistic the Two hit hypothesis is, since NH does not 
exclusively play a role in blocking the differentiation, but it also induces uncontrolled 
proliferation of progenitor cells. In contrast, based on the model proposed by Welch et al10, we 
could consider NH as a driver mutation that plays a causative role in the development of AML but 
needs the cooperation of different oncogenes to enhance its leukemogenic potential.  
Several studies have demonstrated an enforced strong transcription of MEIS1 in NH cellular 
models. A collaborator role of this factor with the fusion protein in leukemogenesis has been 
suggested 26,27,54,55. Co-expression of NH with MEIS1 shortens the period of AML development in 
transplanted mice from 230 to 142 days55. 
On the other hand, several studies have detected the NH fusion gene in patients with 
Chronic Myeloid Leukemia (CML), a clonal stem cell disease caused by the BCR-ABL fusion 
oncoprotein. The BCR-ABL fusion gene is originated by the chromosomal translocation 
t(9;22)(q34;q22), whose derivative chromosome is known as Philadelphia chromosome (Ph). 
Interestingly, there have also been patients who developed NH-induced myeloproliferation and 
subsequently acquired a Ph chromosome in their leukemic cells when AML was diagnosed, 
suggesting that NH and BCR-ABL may interact genetically in human leukemia and influence 
disease progression57,61. In fact, coexpression of NH with BCR-ABL reduces the period to AML in 
transplanted mice even further than MEIS1, from 230 to 21 days55.  
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NH is strongly associated with activating mutations in KIT, NRAS, KRAS, WT-1 and also FLT3-
ITD mutations, each of which is a class I mutation that confers a proliferation or survival 
advantage to hematopoietic cells 8,14,33.  
 
2.6 Other oncogenic NUP fusions 
Although NUP98-HOXA9 is the most frequent, and it is considered the prototype, NUP98 is 
known to fuse to other twenty-eight different partner genes to produce abnormal fusion 
proteins, listed in Table 3. They are caused primarily by balanced translocations and inversions in 
the malignant cells of patients with a wide array of distinct hematopoietic malignancies, mostly 
AML, but also including T-ALL and MDS8,33  
All of these chimeric fusion proteins have the N-terminal half of the NUP98 protein in 
common, which includes the FG repeat region. The C-terminal partner in these chimeras can be 
one of a wide variety of proteins that can be divided into two general classes: 1) homeodomain 
transcription factors and 2) other, typically nuclear and often nucleic acid-binding proteins, such 
as topoisomerases or the putative RNA helicase,DDX1051. 
Just like NH, the other NUP98 fusion proteins also induce proliferation and impair the 
differentiation in hHP. Likewise, they cause MDS that progress to AML in mice with variable 
penetrance, suggesting that cooperating oncogenic events are needed for the complete leukemic 
transformation33,62-66.  However, the molecular mechanisms by which these fusion proteins, 
involving such different partners, cause similar leukemic phenotypes, are completely unknown. 
Many of the NUP98 translocation partner are transcription factors with a DNA binding domain 
(like the homeodomain transcription factors) and it is postulated that, as NH, they deregulate the 
expression of genes involved in hematopoiesis8. In other cases, NUP98 is fused to epigenetic 
regulators, like histone methyltransferase (NSD1, NSD3 or MLL) or histone demethylase 
(JARID1A) and it seems that they modulate gene expression by modifying chromatin at numerous 
regions genome-wide.8,31 However, there is no explanation for those cases in which NUP98 is 
fused to a gene that does not have a DNA-binding activity or that has an unknown function. 
Importantly, NUP98 is not the only nucleoporin implicated in the pathogenesis of 
hematological malignancies. Four other fusion genes involving NUP214 have been described 
(Table 3).  
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Table3: Nucleoporin gene rearrangements in hematologic malignancies. AML = acute myeloid 
leukemia, CML-BC = chronic myelogenous leukemia in blast crisis, MDS = myelodysplastic syndrome, t-AML = 
therapy-related acute myeloid leukemia, t-MDS = therapy-related myelodysplastic syndrome, APL = acute 
promyelocytic leukemia, T-ALL = T-cell Acute lymphoblastic leukemia, B-ALL = B-cell acute lym-phoblastic leukemia, 
and AUL = acute undifferentiated leukemia. (Modified from Takeda et al.; Semin Cancer Bio, 2014) 
 
Rearrangement  Fusion trasncript  Disease  
NUP98 
t(7;11)(p15;p15) 
t(7;11)(p15;p15) 
t(7;11)(p15;p15) 
t(11;12)(p15;q13) 
t(11;12)(p15;q13) 
t(2;11)(q35;p15) 
t(2;11)(q31;p15) 
t(1;11)(q23;p15) 
t(9;11)(q34;p15) 
t(10;11)(q23;p15) 
inv(11)(p15;q22) 
t(11;20)(p15;q11) 
t(9;11)(p22;p15) 
t(5;11)(q31;p15) 
t(8;11)(p11.2;p15) 
t(3;11)(p24;p15) 
Complex (12p13) 
t(11;17)(p15;p13) 
Complex (3p25) 
t(6;11)(q24.1;p15.5) 
Complex (3q29) 
t(11;18)(p15;q12) 
t(4;11)(q21;p15) 
t(10;11)(q25;p15) 
t(X;11)(q28;p15) 
t(3;11)(q12;p15) 
inv(11)(p15;q23) 
t(11;12)(p15;q13) 
t(3;11)(p11;p15) 
 
NUP98-HOXA9 
NUP98-HOXA11 
NUP98-HOXA13 
NUP98-HOXC11 
NUP98-HOXC13 
NUP98-HOXD11 
NUP98-HOXD13 
NUP98-PMX1 
NUP98-PRRX2 
NUP98-HHEX 
NUP98-DDX10 
NUP98-TOP1 
NUP98-PSIP1 
NUP98-NSD1 
NUP98-NSD3 
NUP98-TOP2B 
NUP98-JARID1A 
NUP98-PHF23 
NUP98-ANKRD28 
NUP98-CCDC28A 
NUP98-IQCG 
NUP98-SETBP1 
NUP98-RAP1GSD1 
NUP98-Adducin 3  
NUP98-HMGB3 
NUP98-LOC348801 
NUP98-MLL 
NUP98-RARG 
NUP98-PU1F1 
 
AML/MDS, t-AML/MDS, CML 
CML-BC 
AML,MDS 
AML 
AML 
Pediatric AML 
AML, t-AML 
AML, t-MDS/AML 
t-AML 
AML 
AML, MDS, CML 
AML, t-MDS 
AML, MDS 
Pediatric AML 
AML 
AML (Monoblastic) 
AML (Megakaryoblastic) 
AML 
MDS/AML 
AML (Megakaryoblastic), T-ALL 
Biphenotypic T-ALL/AML 
Pediatric T-ALL 
Adult T-ALL 
T-ALL 
t-AML 
AML 
AML 
APL 
t-AML 
NUP214 
t(6;9)(p23;q34) 
del(9)(q34) 
der(5)t(5;9)(q35;q34) 
Amplified episomes  
 
DEK-NUP214 
SET-NUP214 
SQSTM1-NUP214 
NUP214-ABL1  
 
AML 
T-ALL, AML, AUL 
T-ALL 
T-ALL, B-ALL  
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3 ENHANCERS AND TRANSCRIPTIONAL REGULATION  
Enhancers are DNA cis-regulatory elements that enable the regulation of target gene 
expression and that are able to function close to the promoters or at large distances upstream or 
downstream from them. Importantly, multiple activators and repressors can bind and modulate 
an individual enhancer and multiple enhancers can determine a single gene’s precise pattern of 
expression67. Currently, there is a growing number of studies that point to the importance of 
enhancers in orchestrating important transcriptional networks and highlight the fact that the 
misregulation of enhancer properties is central to the pathogenesis of cancer and other diseases 
known as “enhanceropathies”. 
The initial recognition of enhancers requires pioneer transcription factors that can bind to 
their consensus sequences and facilitate the binding of additional transcription factors to open 
chromatin. GATA1, FOX proteins or Pu.1 are some of the identified pioneer factors68. 
Additionally, the communication between enhancers and promoter regions seems to be 
necessary for the proper transcriptional regulation. Cohesin has been validated as a major 
regulator of this enhancer-promoter interaction. Its ability to hold together sister chromatids is 
used to form or stabilize loops of chromatin that bring enhancers and promoters in close 
proximity69 (Figure 11A). 
 
 
 
 
 
Figure 11: Structure of enhancers. (A) Schematic representation of the loop that enables the enhancer-promoter 
communication. Chip (in Drosophila) or LDB1 (the mammalian homolog) is thought to interact with DNA-binding 
transcription factors (DBDs) at enhancers and promoters and through a self-interaction domain to help bridge this 
communication. The ring-like cohesin structure is thought to hold the enhancer and promoter together. (B-C) 
Schematic representations of the chromatin signatures associated with different enhancer states and the mediators 
responsible for each of them: H3K4me1 implemented by MLL in poised and active enhancers (A), H3K27ac implemented by 
CBP/p300 that is characteristic of active enhacncers (B) and the removal of the H3K4me1 in enhancer dcommissioning. (Images 
modified from E. Smith & A. Shilatifard, Nat Struct Mol Biol. 2014) 
 
A B 
C 
D 
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Enhancers have been classified into poised and active states. Chromatin signatures in these 
different states have been identified. Both classes maintain the enrichment for H3K4me1 that is 
implemented by MLL3 and MLL4 (lysine (K)-specific methyltransferases, components of 
COMPASS family). During differentiation, however, many enhancers become silenced by losing 
the H3K4me1 that is removed by the demethylase LSD, in a process called enhancer 
decommissioning. H3K27ac, implemented by CBP and p300, is present in active enhancers. Thus, 
CBP and p300 are found at active promoters and their occupancy at intergenic or intragenic 
regions has indeed served as a useful and convenient marker for enhancers (Figure 11 B-D). UTX 
is the H3K27 deacetylase that would remove the active mark and enable the return to poised 
state. Active enhancers also have the ability to recruit Polimerase II (PolII)70.Most of them are 
transcribed by PolII generating transcripts named enhancer RNAs (eRNA). The appearance of 
eRNAs precedes the activation of nearby genes, but their function is not completely understood 
yet 67.  
A number of genome-wide studies on transcription factor binding in multiple different cell 
systems have shown that many transcription factors tend to co-localize with other factors on 
chromatin71. More recently, the existence of super-enhancers, which are large genomic regions 
(several kilobases) containing clusters of closely spaced transcription factor binding regions, has 
been demonstrated. These large super-enhancers are characterized by very high levels of 
Mediator subunit 1 (MED1) binding and seem to regulate cell identity71-73. Hence, the fact that 
enhancers harbor binding sites for a large number of transcription factors highlights the 
importance of these regulatory elements in normal cell functions and points to that the global 
network of enhancer–promoter interactions may be much more complex than it was previously 
believed74.  
Enhanceropaties are originated by the alteration of the enhancer sequences or mutations in 
proteins that either directly interact with enhancers or regulate enhancer function67,75. 
Importantly, many oncogenes or tumor suppressor genes are regulated by enhancers but also, 
many oncogenes are transcription factors that regulate the gene expression by interacting with 
enhancers. All of this helps to explain the potential role that these regulatory regions seem to 
play in cancer pathogenesis. Pharmacological approaches that target transcription factors that 
are recruited to the enhancers of tumor suppressor genes or oncogenes (“Enhancer Therapy”), 
are being developed with promising results in the fight against enhancer-mediated cancers75. 
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NUP98-HOXA9-associated AML is one of the most aggressive forms of leukemia, highly 
refractory to intensive treatment and with a dismal overall survival. Current knowledge about 
the molecular mechanisms underlying this fusion protein, something that would trigger the 
identification of new and more efficient therapeutic targets, is still limited.  
This project was aimed at studying the oncogenic role of this leukemic fusion gene in a 
human cellular modeled context, with the purpose of providing some proofs of concept that 
allow to explore a better designed targeted therapy for these patients. For this aim our 
objectives were: 
 
1. Generate in vitro human cellular models that constitutively express NUP98-HOXA9.  
 
2. Based in these models: 
 
a. Identify and analyze the specific DNA binding regions of NH, their target genes 
and the global expression profile induced by the fusion protein. 
 
b. Identify new NH-interacting proteins and the role of each moiety of the chimera 
in the NH driven leukemogenesis  
 
c. Describe some of the molecular mechanism of action of this fusion protein 
 
d. Propose new therapeutic targets and a possible effective treatment for these 
patients. 
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1 CELLULAR MODELS  
1.1 Cell culture  
hHP (CD34+) were purified using immunomagnetic beads (Miltenyi Biotech, Germany) from 
Human umbilical cord blood (CB). hHP were cultured in Iscove’s modified Dulbecco’s media 
(IMDM) containing 20% BIT 9500 Serum substitute (STEMCELL Technologies), 1% penicillin-
streptomycin (Invitrogen), 0,2% β-mercaptoethanol and 10 ng/ml SCF, megakaryocyte growth 
and development factor (TPO), FLT3 ligand (FLT3L), IL-3, and IL-6. 
HEK293T and HEK293FT cells were cultured in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen).  
1.2 Retroviral constructs  
NUP98-HOXA9 coding region sequence was PCR amplified from cDNA from a patient with 
primers, forward 5’-ATGTTTAACAAATCATTTGGAACACCCT-3’, and reverse 5’-
TCACTCGTCTTTTGCTCGGTCTTTGTTG-3’ to be cloned into pMSCV-IRES-GFP retroviral vector, and 
named pMSCV-NH. The coding region of HOXA9 was amplified from a cDNA control with primers, 
forward 5’-ATGGCCACCACTGGGGCCCTGGGCAACT-3’, and reverse 5’-
TTACTCGTCTTTTGCTCGGTCTTTGTTG-3’. It was cloned into the same retroviral vector and named 
pMSCV-HOXA9.  The NUP98 coding region sequence was kindly provided by Dr Maureen A. 
Powers and PCR amplified with primers, forward 5’-ATGTTTAACAAATCATTTGGAACACCCT-3’, and 
reverse 5’-TCACTGTCCTTTTTTCTCTACCTGAGGT-3’. It was cloned into the same retroviral vector 
and named pMSCV-NUP98. We included FLAG and HA as tag in the three coding regions. 
The PBX3 coding region was amplified from the vector PBX3-pSP65 (Plasmid #21033 from 
Addgene, http://www.addgene.org) and cloned into the pMSCV-IRES-GFP retroviral vector and 
named pMSCV-PBX3, using the forward primer 5’-ATGAAACCAGCGCTCTTCAGCGTCCTGT-3’ and 
the reverse 5’-GTTAGAGGTATCCGAGTGCACACTTC-3’ with FLAG as tag.  
1.3 Retroviral production and transduction 
Retrovirus for each construct was produced in 293FT cells by cotransfecting viral plasmids 
along with M57 and RD114 packaging plasmid in a 1:1.2:0.3 ratio using Calcium-phosphate 
protocol. 12 hours later, the precipitate was washed away, and viral supernatants were collected 
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at 24 and 36 hours. The supernatant was centrifuged at 1800 rpm and filtered through a 0.45μm 
filter76,77.  
Transduction of hHP (CD34+ cells) was carried out on plates coated with Retronectin (Fisher 
Scientific, Pittsburgh, PA) preloaded with virus. We transduced 2 × 106 cells with 3 rounds of 
retrovirus using retronectin-coated dishes in the same media used for hHP culture with the 
addition of 8 μg/ml Polybrene. Transduction of 293FT cells was performed in the same way but 
without Retronectin.  
hHP and 293FT cells were stably transduced with the different retroviral vectors and GFP 
positive cells were sorted on BD Influx™ cell sorter (BD Biosciences).  
1.4 Patient samples 
The leftover material of 8 AML t(7;11)(p15;p15) samples were used for RNA extraction. 
Three of them came from the MLL Münchner Leukämielabor GmbH (München, Germany) and 
the other five from the cytogenetic laboratories of the University of Navarra (Pamplona, Spain). 
Informed consent was obtained according to the Declaration of Helsinki (October 2008). 
 
 
2 IDENTIFICATION OF GENOMIC BINDING SITES 
 
2.1 Chromatin immunoprecipitation sequencing (ChIP-seq) 
Chromatin immunoprecipitation (ChIP) was performed as described before78. 15 min of 
formaldehyde fixation in ≈ 10 millions of cells from 293FT models were performed to yield the 
best combination of in vivo fixed chromatin, high DNA recovery and small average size of 
chromatin fragments. In our analyses, chromatin was sonicated and sheared to an average 
length of 200 bp. Immunoprecipitation was carried out using Protein A/G Plus-Agarose beads 
(Santa Cruz) and the antibodies anti-FLAG M2 (Sigma-Aldrich) and anti-HA tag antibody-ChIP 
Grade (ab9110, abcam). DNA was purified with phenol/chlorophorm extraction followed by 
ethanol precipitation. Eluted DNA fragments were analysed by ultrasequencing.  Libraries was 
constructed using the ChIP-seq sample preparation kit (Illumina, San Diego, California, USA) and 
were sequenced in a Genome Analyzer IIx (GA2, Illumina) single 36-base read run.  Raw 
sequences were defined as reads passing purity filter before genome alignment. Alignment was 
performed with BWA79 versus the human sequence assembly (GRCh37/hg19, Feb 2009) under 
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default settings permitting alignments with 1 mismatch in 40 base reads. Peak detection was 
performed with MACS 2.080 following developer’s technical recommendations (pvalue cutoff for 
peak detection = 1x105). MACS pipeline was used to find differential peaks in pair-wise 
comparisons. Significant ChIP-seq peaks were stablished at FDR ≤ 5%. The generated bed files 
were uploaded to the USCS genome browser (http://genome.ucsc.edu/) to visualize the 
enrichment peaks obtained with Findpeaks analysis. Venn diagrams used for gene set 
comparisons were performed at http://www.cmbi.ru.nl/cdd/biovenn/. 
2.2 In silico data analysis 
Gene lists were functionally annotated using Ingenuity Pathways Analysis software 
(Ingenuity® Systems, http://www.ingenuity.com/products/ipa). Enrichment of genes associated 
with specific biological functions, canonical pathways and diseases was determined relative to 
the Ingenuity knowledge database. The significance level cut off used pas p > 0.05 after 
Benjamin-Hoechberg multiple testing correction (B-H p-value). 
MEME-ChIP81 was employed to find enriched motifs in significant ChIP-seq peaks.  They were 
also scanned for detect  individual HOXA9, MEIS1 and HOXA9/MEIS1/PBX motifs using FIMO tool 
(from MEME Suite web server) 82. oOPOSSUM83 (http://opossum.cisreg.ca/oPOSSUM3/) was 
used to identify the over-represented transcription factor binding sites from the top 100 NH 
target genes. (Figure 12) 
 
 
Figure 12: Overview of the 
bioinformatics tools used for the motif 
analysis. MEME-ChIP scans unaligned 
sequences from ChIP-seq analysis to identify 
described motifs. FIMO identifies a set of 
selected motifs in unaligned sequences from 
ChIP-seq analysis. oOPOSSUM identifies 
known motifs of transcription factors in the 
regulatory regions of a gene set (Image 
modified from Bailey et al
84
) 
64 
 
3 VALIDATION OF TARGET GENES 
 
3.1 qChIP 
ChIP was performed as described above (ChIP-seq paragraph) with 2X106 cells per sample 
(hHP or 293FT cellular models). Quantitative PCR (qPCR) of eluted DNA was performed in 12ul 
with SYBR Green dye (Applied Biosystems) for validating the selected target genomic regions of 
NH obtained from the ChIP-seq data on an ABI 7900HT sequence detection system. Three 
biological replicates were performed and the input DNA, ‘unbound’ (wash) fraction of the no 
antibody control and the ‘bound’ fractions for each antibody was included for each experiment. 
In a house designed primers used for validation are listed in Table 4. The amount of 
immunoprecitpiated DNA relative to input was calculated for each experiment.  
 
Table 4: qChIP primers  
 
EN
H
A
N
C
ER
S 
HOXA9  
5’- GCTTACAATACCTCCTCCATCAA-3’  
5’- CTCTAAACCTCAGGCCACATC -3’  
MEIS1  
5’- TGCCATTCATACCCTGCTATAC -3’  
5’- TTGGAATCCTAGTGGATGTTTCT -3’  
PBX3  
5’- GCTACTCCAGGAACACTAAACC -3’  
5’- CGGTCACAGTCAGAGAGAAATG -3’  
MET  
5’- GGGCATTCTGCTCCTGTTAT -3’  
5’- ATCCCAAGCGGAATATACTAACC -3’  
BRAF  
5’- CACAAGGGCACCTGTGAATA -3’  
5’- TGGATTGCATCATAACCCTGAA -3’  
AF9  
5’- CCTTAGGCACCCACATGTATATT -3’  
5’- GCCTCTGATTAGCCTGTGTATG -3’  
NF1  
5’- GGTACAGGTCTATATGTGTGTCTAAA -3’  
5’- AGAGTCTGCCATTAACCTTGTAA -3’  
PTEN  
5’- GTACATGACCTTGGACGAGTTAT -3’  
5’- CTCCATTCGACCCTCACAAA -3’  
P
R
O
M
O
TE
R
S 
 
HOXA9  
5’- CGGCACGATCCCTTTACAT -3’  
5’- CCCGTCCAGCAGAACAATAA -3’  
MEIS1  
5’- TGTAAGACGCGACCTGTTATG -3’  
5’- GCGTGTGTAAAGTGTGTGTTG -3’  
PBX3  
5’- TCTTTCTTCTCCTCCCTCGT -3’  
5’- CAGCATCCTGGATTGATCGT -3’  
AFF3  
5’- CTCTTTAGGAGCCACGATGATAC -3’  
5’- CTGGGTGTCGACTTCAAACT -3’  
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PTEN  
5’- ATGTGGCGGGACTCTTTATG -3’  
5’- GCGGCTCAACTCTCAAACT -3’  
BIRC3  
5’- GCAGAGCTTTCCACCATGAA -3’  
5’- GGTCAACTTCTCCAGGCTACTA -3’  
FILIP1L  
5’- TGAAGTCCCTGAAGCAACAA -3’  
5’- CTGTCGGGCTAACAAAGTCA -3’  
SMAD1  
5’- TGTCTCGTTCCTTTCCCTTTAC -3’  
5’- CTAACAAAGACAGGGAGCAGAG -3’  
 
3.2 RNA extraction and quantitative Real-time RT-PCR  
RNA from the different hHP cellular models was extracted using the RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s instruction and TaqMan® Gold RT-PCR Kit 
(Applied Biosystems, Foster City, California, USA) was used for the reverse-transcription.  The 
qRT-PCR was performed on 384-well plates, with each independent cDNA included in triplicate, 
using quantitative PCR with SYBR Green dyes (Applied Biosystems) on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems), following the manufacturer’s protocol. The expression of the 
endogenous human housekeeping gene GAPDH was used to normalize the data and they are 
expressed as the mean of 2-ΔCt values obtained for each sample after normalization with normal 
human hematopoietic progenitors (SDS Program; Applied Biosystems). Statistical significances on 
level of expression of the selected target genes were determined with significance levels of 
P<0.05 and P<0.01 calculated using T-test. Dissociation curves were performed for each set of 
primers. In a house designed primers are listed in Table 5. 
To analyse the expression of hsa-miR-181b in hHP-NH cellular model, total RNA, including 
miRNAs, was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions for Purification of total RNA, including Small RNAs from Animal Cells. 
10 ng of RNA per sample were reverse transcribed using the MicroRNA Reverse Transcription Kit 
(Applied Biosystems). Three replicates of cDNA were prepared for each sample. qRT-PCR was 
performed using TaqMan Fast Universal PCR Master Mix on a 7500 Fast Real-Time PCR System 
following the manufacturer’s protocol. Each independent cDNA was run in triplicate in a 384-well 
plate. Data were normalized on the expression of the artificial Homo sapiens miRNA control 
RNU19 and relative expression was calculated using the comparative Ct method as described 
above. A pre-developed TaqMan Assays (Applied Biosystems) primer for has-miR-181b 
(462578_mat) was used. 
66 
 
Table 5: Sybr Green qPCR primers  
 
HOXA9  
5’-GTGGTTCTCCTCCAGTTGATAG-3’  
5’-AGTTGGCTGCTGGGTTATT-3’  
MEIS1  
5’-CTAACACACCCTTACCCTTCTG-3’  
5’-TCTATCATGGGCTGCACTATTC-3’  
PBX3  
5’-CATCACAGTGTCACAGGTATCC-3’  
5’-CAGCATAGAGGTTGGCTTCTT-3’  
MYB  
5’-TGTAGGGAGAGGTGGCATAA-3’  
5’-GTCTCTTGTGTGCCTGGTAAA-3’  
MEF2C  
5’-GCAACAGCAACACCTACATAA -3’  
5’-GTAGAAGGCAGGGAGAGATTTG-3’  
HOXA7  
5’-AGTTCCACTTCAACCGCTAC-3’  
5’-CCTTCGTCCTTATGCTCTTTCT-3’  
BIRC3  
5’-CAAGCCAGTTACCCTCATCTAC-3’                 
5’-CTGAATGGTCTTCTCCAGGTTC-3’  
BIRC2  
5’-CTAGTCTGGGATCCACCTCTAA-3’             
5’-TGTTCCAAGGTGGGAGATAATG-3’  
LMO2  
5’-GATGACAATGCGGGTGAAAG-3’  
5’-GTCAGAGTTGATGAGGAGGTATC-3’  
RARA  
5’-CGAACAACAGCTCAGAACAAC-3’       
5’-GGCGAACTCCACAGTCTTAAT-3’  
PML  
5’-TGTACGCCTTCTCCATCAAAG-3’  
  5’-GACTCCATCTTGATGACCTTCC-3’  
 
 
3.3 Luciferase assay   
Luciferase constructs were made following amplification of the three selected regulatory 
genomic regions of HOXA9, PBX3 and MEIS1 by subcloning in the pGL3-Promoter Vector 
(Promega Biotech Ibérica S.L) with the firefly luciferase gene, previous to the SV40 promoter. 
PCR products were obtained using the following primers: HOXA9, sense 5’-CACGG 
TACCGGGTTTCCCAGCTTTTTCTC-3’, antisense 5’-TTCCTCGAGGAGAAGGGGGACAAGAGGAC-3’; 
PBX3 sense 5’-CACGGTACCTGTTCTGAGACTGCCCATTG-3’, antisense 5’-TTCCTCGAGA 
AATTGCTGCACAGGTGAGA-3’; MEIS1 sense 5’-CACGGTACCCCCCTTTAACTTGAGAATCAGC-3’, 
antisense 5’-TTCCTCGAGTTCAATGCAGCAGCTGAACTAT-3’. The insert identities were verified by 
sequencing and the following specific bacterial artificial chromosomes (BACs) were used as a PCR 
template: RP11–197I05 (HOXA9), RP11-638B02 (PBX3) and RP11-678O18 (MEIS1). A total of 105 
HEK293FT cells were transfected with 500 ng of the firefly luciferase reporter vector containing 
the HOXA9, PBX3 and MEIS1 regulatory genomic regions and 200 ng of the control vector 
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containing Renilla luciferase pRL-CMV (Promega) using Calcium-phosphate mediated transfection 
protocol. Five hundred nanograms of pMSCV-NH or the empty vector were used to analyze the 
effect of NUP98-HOXA9 expression on luciferase signal. Luciferase assays were performed 48 h 
after transfection using the Dual Luciferase Reporter Assay System (Promega). The results were 
expressed as relative luciferase activity (%), calculated by normalizing the ratio of firefly 
luciferase to Renilla luciferase luminiscence. The reporter assay was independently performed 
three times for each of the experiments, including all samples in triplicate. 
3.4 Gene expression microararys  
RNAs from three different clones of hHP-NH cellular model and 5 primary samples from 
patients with t(7;11)(p15;p15) were isolated and hybridized in Array SurePrint G3 Human Gene 
Expression 8x60K v2 (Agilent Technologies) in NIMgenetics (www.nimgenetics.com, Madrid, 
Spain). Arrays were examined using the DNA Microarray Scanner C (Agilent Instruments) and 
microarray background subtraction was carried out using normexp method. To normalize the 
dataset, we performed loess within arrays normalization and quantiles between arrays 
normalization. Differentially expressed genes were obtained by applying linear models with R 
limma package85 (Bioconductor project, http://www.bioconductor.org). To account for multiple 
hypotheses testing, the estimated significance level (p value) was adjusted using Benjamini & 
Hochberg False Discovery Rate (FDR) correction. Those genes with FDR <0.05 were selected as 
differentially expressed between hHP-NH or patient samples and controls (hHP-empty vector or 
hHP wt, respectively). 
3.5 Gene Set Enrichment Analysis (GSEA) 
We applied gene set enrichment analysis (GSEA) to integrate global gene expression data and 
the enrichment in NH targets. Genes were ranked based on limma moderated t statistic. After 
Kolmogorov-Smirnoff testing, those gene sets showing FDR <0.05, a well-established cut-off for 
the identification of biologically relevant gene sets 86, were considered enriched between classes 
under comparison. The enrichment score from the gene set after it has been normalized across 
analyzed gene set (NES) was also shown. 
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4 EVALUATION OF TREATMENT EFFICACY 
 
4.1 Viability assay  
HXR9 and CXR9 peptides were synthesized by Biosynthesis® (http://www.biosyn.com/) as 
previously described47. 5x103 hHP-NH/hHP-emtpy vector sorted cells were plated per well in 96-
well plates in triplicate and allowed to recover for 20 hours. Then they were treated with 
different doses of the active peptide HXR9 or the control peptide CXR9 in a range of 0 µM to 250 
µM for 48 hours to determine the LC50. Cell viability was assessed by adding WST1 cell 
proliferation reagent (Roche, Basel, Switzerland) and reading the plates at 450 nm to measure 
optical density, according to the manufacturer's instructions. Then, we treated the hHP-NH with 
13uM HXR9 (LC50) and measured cell viability at 0h, 24h, 48h, 72h and 144h.  
To assess the effect of Panabinostat (LB589, purchased from Selleck) in hHP-NH, sorted 
cells were plated in triplicate with titrating doses of the drug (purchased from Selleck) (range, 
0 µM to 1 µM) for 72 hours. Cell viability was analysed in a similar manner, using WST-1. 
For each assay, three independent clones of hHP-NH/hHP-empty vector were used in three 
different experiments. 
4.2 CFU assay  
Aliquots of 8x103 or 4x103 of the hHP-NH/hHP-empty vector sorted cells were plated into 
35 mm culture dishes in 1,5 ml of MethoCult M4230 methylcellulose medium (StemCell 
Technologies) containing 20% of BIT 9500 Serum substitute (STEMCELL Technologies) and 
20ng/ul  each of human recombinant SCF, IL-3, IL-6 and GM-CSF, and 3U/ml of EPO. Two aliquots 
of each cellular model were treated with 13uM of both HXR9 and CXR9 peptides (LC50) or with 
4nM of LBH589. Cultures were incubated at 37°C in a humidified atmosphere for 10 days and 
then the number of colonies was counted for each case. This experiment was performed with 
two different clones of hHP-NH/hHP-empty vector for each treatment. 
CFU assay with hHP-NUP98 cellular model was performed in the same manner but without 
treatment. 
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4.3 Apoptosis assay 
3.75x105 hHP-NH/hHP-emtpy vector sorted cells were plated per well in 24-well plates in 
triplicate and allowed to recover for 20 hours. Then, the cells were treated with HXR9/CXR9 
(13uM and 30uM) or LB589 (10nM and 30nM) for 24 hours. Apoptosis was assessed after the 
treatment using FITC annexin V and annexin V binding buffer (BD Biosciences) and DAPI staining 
(to exclude the nonviable cells) on FACSCanto II (BD Biosciences, San Jose, California, USA) 
following the manufacturer’s instructions.  
 
5 PROTEIN-PROTEIN INTERACTION STUDY 
 
5.1 Protein co-immunoprecipitation and Immunoblotting  
For p300, HDAC1, MEIS1 and PBX3 co-immunoprecipitation with NUP98-HOXA9, 
4.106 HEK293FT cells were transfected with pMSCV-NH and/or pMSCV-HOXA9 vectors. 48h post-
transfection, cells were washed with cold PBS + protease inhibitors (Roche), and lysed for 1 hour 
at 4°C with 0.5 ml of lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl and 1% NP-40 and 
protease inhibitors (Roche)). The lysate was centrifugated at 13,000×rpm for 15 min at 4°C. The 
supernatants were transferred to new tubes and were precleared using 20ul Protein A/G Plus-
Agarose beads (Santa Cruz) for 30 min at 4°C. Then, in accordance with the manufacturer’s 
instructions, the different antibodies were added to the supernatants (anti-p300 (Santa Cruz), 
anti-HDAC1 (Thermo Scientific), anti-MEIS1 ChIP Grade (Abcam) and anti-PBX3 (Santa Cruz).  
After overnight incubation at 4°C, 20ul Protein A/G Plus-Agarose beads were added and 
incubated for another 2 hours. Beads were washed with 900 µl of lysis buffer 5 times, followed 
by centrifugation at 2400×rpm for 2 min at 4°C. Beads were washed one time with cold PBS and 
bound proteins were eluted by boiling with 40 µl of 2X Laemmli Buffer (100mM Tris-HCl pH 6.8, 
20% Glycerol, 4% SDS, 300 mM β-mercaptoethanol, 0.2% Bromophenol Blue) for 3 min at 95°C. 
Input lysates and immunoprecipitated proteins were loaded onto SDS-PAGE gels (9% gel) 
followed by immunoblotting. After transfer, PVDF membranes (Millipore, Billerica, 
Massachusetts, USA) were incubated with anti-FLAG M2 (Sigma-Aldrich) primary antibody to 
detect Nup98-Hoxa9 and/or Hoxa9 and with anti-GAPDH or α-tubulin (monoclonal antibodies, 
CNIO) as endogenous control. 
 
70 
 
5.2 Mass Spectrometry  
We used the 293FT-NH, 293FT-HOXA9 and 293FT-NUP98 models to conduct the 
corresponding immunopreticiptations using anti-FALG antibody (Sigma Aldrich), followed by 
mass spectrometry in three replicates for each model. Cellular model transducted with the 
retroviral empty vector with GFP gene flanked by FLAG-tag was submitted to the same process 
and used as a control in the assay.  
Sample Preparation  
Proteins in the pull-downs were subjected to label free proteome analysis. Samples were 
digested by means of the standard FASP protocol1. Briefly, samples were resuspended in UT 
buffer (8M urea in 100 Mm Tris-HCl, pH=8.01). Proteins were then reduced with 10 mM DTT, 
alkylated using 50 mM iodoacetamide for 20 min in the dark and the excess of reagents was 
washed out with UA twice. Proteins were digested with endoproteinase Lys-C (Wako) during 6 
hours in a wet chamber (1:50 enzyme to substrate ratio). Finally, samples were diluted in 50 mM 
ammonium bicarbonate to reduce the urea concentration to 1M and subsequently digested with 
Trypsin Gold (Promega) overnight at 37 °C. Resulting peptides were further desalted and 
concentrated using homemade reversed phase micro-columns filled with Poros Oligo R3 beads 
(Life Technologies). The samples were dried using the Speed-Vac and dissolved in 30 µL of 0.1% 
formic acid (FA). 
 
LC-MS/MS analysis 
Desalted peptides were separated by reversed-phase chromatography using a nanoLC Ultra 
system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo Fisher 
Scientific) via nanoelectrospray source (ProxeonBiosystem). Peptides were loaded onto the 
column (Dr. Maisch, Reprosil-
column step (Prot Trap Column 0.3 x 10 mm, ReproSil C18-AQ, 5 µm, 120Å, SGE), during 10 min 
with a flow 
with a 120 min linear gradient (buffer A: 2% ACN, 0.1%FA; buffer B: 100% ACN, 0.1%FA) at 300 
nL/min. The peptides were directly electrosprayed into the mass spectrometer using a PicoTip 
emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) a 1.4 kV spray voltage with a heated 
capillary temperature of 325°C and S-Lens of 60%. Mass spectra were acquired in a data-
dependent manner, with an automatic switch between MS and MS/MS scans using a top 20 
method with a threshold signal of 800 counts. MS spectra were acquired with a resolution of 
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60000 (FWHM) at 400 m/z in the Orbitrap, scanning a mass range between 350 and 1500 m/z. 
Peptide fragmentation was performed using collision induced dissociation (CID) and fragment 
ions were detected in the linear ion trap. The normalized collision energy was set to 35%, the Q 
value to 0.25 and the activation time to 10 ms. The maximum ion injection times for the survey 
scan and the MS/MS scans were 500 ms and 100 ms respectively and the ion target values were 
set to 1E6 and 5000, respectively for each scan mode. 
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1 NUP98-HOXA9 human cellular models construction 
First of all, we cloned the cDNA of NUP98-HOXA9 fused to FLAG-tag at the 3’-end and HA-
tag at the 5’-end into the retroviral vector pMSCV-IRES-GFP (Figure 13A). We generated 
retroviruses in HEK293T cells and efficiently transduced both Human Hematopoietic Progenitors 
(hHP) and the HEK293FT human cell line. hHP (CD34+) were isolated from human cord blood 
samples using CD34 immunomagnetic microbeads and maintained in cytokine-stimulated 
suspension culture. Green Fluorescence protein (GFP) allowed us to select the transducted cells 
using BD Influx™ cell sorter. Thus, we established two human cellular models that constitutively 
express NUP98-HOXA9: hHP-NH and 293FT-NH (Figure 13B and C).  According to the published 
data27,53, long-term cultures of the hHP-NH cellular model clearly showed an increase in 
proliferation due to the presence of the fusion protein, supporting so far the fitness of the model 
for further studies (Figure 13D).  However, hHP-NH cells grow 3.5 weeks more, on average, than 
scramble cells, but only up to 8 weeks. This fact makes this cellular model very hard to work with, 
especially if we need to obtain big amounts of cellular material. Therefore, to solve this problem, 
we have also created the 293FT-NH model from a human immortalized cell line. 
 
 
 
 
 
 
 Figure 13: NUP98-HOXA9 human cellular models construction. (A) Representation of the pMSCV-NH 
retroviral vector. ((B) hHP-NH cellular model: Microscopy image of hHP transduced with pMSCV-NH retroviruses and 
sorted (GFP+) (C) 293FT-NH cellular model: Microscopy image of HEK293FT cells transduced with pMSCV-NH 
retroviruses and sorted (GFP+) D) Long-term culture of hHP-NH and hHP-empty vector cellular models for 62 days. 
A 
D B 
hHP-NH 
C 
293FT-NH 
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2 Identification of NUP98-HOXA9 genomic binding regions  
To explore the transcription factor role of NH, we decided to perform a ChIP-seq analysis in 
order to identify its DNA binding sites, trying to extract from this data an idea about the possible 
oncogenic mechanism triggered by the fusion protein.  
ChIP-seq approach consists in a chromatin immunoprecipitation (ChIP) followed by a 
massive sequencing of the eluted DNA fragments. We used the 293FT-NH cellular model to 
immunoprecipitate NH attached to the DNA, using an anti-FLAG antibody. The sequencing of 
these NH-binding sites allowed us to identify 4471 significant genomic regions (FDR < 0,05), 
located within a 5 kb distance from annotated Transcrption Start Sites (TSS), that corresponded 
to regulatory regions of 1363 different genes and 17 miRNAs (Figure 14A, Table 6 and Table S1). 
A detailed sequence analysis of all DNA bounded NH regions using MEME-ChIP84 identified a 
significant enrichment in consensus binding motifs of important leukemic transcription factors, 
as detailed in Table 7. We detected the presence of binding sites for several HOX genes, including 
HOXA9, which confirms the importance of DNA binding of the homeobox domain of this fusion 
protein.  We also identified a highly significant enrichment of the motif CA/gTTT, present in one-
third of all binding sites. This motif has not previously been associated with any known 
transcription factor; it appears to be a novel specific binding site for NH. 
 
Table 6: Target miRNAs of NUP98-HOXA9 identified in the ChIP-seq 
 
miRNA FDR 
hsa-miR-181A2 0.00 
hsa-miR-181b 0.00 
hsa-miR-586 0.00 
hsa-miR-548F1 0.00 
hsa-miR-581 0.00 
hsa-miR-550-1 0.00 
hsa-miR-194-1 0.00 
hsa-miR-128-1 0.00 
hsa-miR-615 0.00 
hsa-miR-297 0.00 
hsa-miR-125B2 0.00 
hsa-miR-576 0.00 
hsa-LET7I 0.00 
hsa-miR-181A1 0.01 
hsa-miR-1245 0.02 
hsa-miR-30A 0.02 
hsa-miR-626 0.04 
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 Figure 14: Identification of NUP98-HOXA9 genomic binding regions (A) Venn diagrams of the overlapping 
NH, HOXA9 and NUP98 target genes indentified with the ChIP-seq approach on HEK293F human models (FDR<0.05). 
(B) Plot that represents the localization of NH binding sites in distance (Kb) from the TSS. (C) H3K4me1 qChIP fold 
enrichment on the selected NH target regions. MEIS1 promoter region was used as a negative control. Average of 3 
experiments is shown. Error bars represent SEM.Plot that represents the main functions of the NUP98 wt target 
genes (IPA output) (D) PolII qChIP fold enrichment on the eight selected NH target regions. Average of 3 experiments 
is shown.  
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Table 7: Identification of DNA binding motifs in NH target regions using MEME-ChIP. 
 (MEME-ChIP p-value <  1.10-6) 
 
 
A further analysis of these binding sequences indicated that they were preferentially located 
more than 1 kb upstream from the TSS (only less than 20% of them located at promoter regions) 
(Figure 14B). This distribution strongly suggested that the enhancer regions likely were the 
preferred binding targets of the fusion gene. The chromatin mark that best predicts both poised 
and active enhancers is the monomethylated form of H3 lysine 4 (H3K4me1)67. We performed a 
ChIP by immunoprecipitating this epigenetic mark both in presence and absence of the fusion 
protein using the 293FT cellular models. Then, from the eluted DNA, we performed a 
quantitative PCR to analyzed the binding sites of NH corresponding to eight selected target genes 
with an undoubted role in myeloid leukemogenesis (MEIS1, HOXA9, PBX3, MET, BRAF, AF9, PTEN 
and NF1). We were able to demonstrate an enrichment of H3K4me1 at the eight genomic 
regions  (Figure 14C). We also detected an increase in the presence of PolII at these NH-binding 
sites when the fusion protein is expressed, which is consistent with an active form of 
enhancers67,70,87 (Figure 14D). In addition, we applied the oPOSSUM system83, an in silico analysis 
to identify over-represented transcription factor binding sites in the regulatory regions from a set 
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of genes. We analysed the top 100 NH target genes obtained in the ChIP-seq (FDR < 0,0001). The 
transcription factors that may be binding to the same regulatory regions than NH are listed in 
Table 8 (only shown those with a Fisher score <0,01). Notably, there is an over-representation of 
FOX proteins, considered pioneer factors that are responsible for the initial recognition of 
enhancers and that facilitate the binding of additional transcription factors to those regulatory 
sites 67. Taken together these approaches support a working model for NH where its role in 
transcriptional regulation is mostly mediated by its binding to enhancers.   
 
Table 8: Identification of known transcription factor binding motifs in NH target regions using 
oOPOSSUM   
(Fisher score < 0.005. Fox proteins in orange) 
 
TRASCRIPTION 
FACTOR 
Fisher score 
HLF 3,70x107 
NFIL3 4,68x106 
CF2-II 1,63x105 
Broad-complex_1 3,65x105 
ATHB5 5,68 x105 
HMG-IY 6,03 x105 
Ddit3-Cebpa 7,43 x105 
hb  8,19 x105 
HNF1A 8,45 x105 
Broad-complex_4 9,96 x105 
Lhx3 1,30 x104 
Athb-1 1,64 x104 
SQUA 2,79 x104 
Foxd3 2,83 x104 
Lhx3 4,67 x104 
Foxq1 6,74 x104 
Broad-complex_3 8,66 x104 
NKX3-1 1,65 x103 
Foxa2 2,17 x103 
FOXI1 2,30 x103 
TBP 2,30 x103 
Ovo  2,66 x103 
MYB.ph3 2,81 x103 
FOXD1 3,64 x103 
SOX9 4,83 x103 
PEND 6,88 x103 
SRY 8,40 x103 
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3 Identification of HOXA9 and NUP98 wt genomic binding 
regions 
We further investigated the functional contribution to the DNA binding profile of the two 
moieties that compose the fusion protein. We cloned the coding region of HOXA9 wt and NUP98 
wt fused to FLAG-tag and HA-tag in the retroviral vector pMSCV-IRES-GFP (Figure 15A). We then 
established two new cellular models, 293FT-HOXA9 and 293FT-NUP98, which allowed us to 
perform separate ChIP-seq analyses. By combining the obtained ChIP-seq data (Tables S3 and 
S4), we observed that one third of the NH target genes were common to HOXA9 wt target genes 
(Figure 14A), indicating that the homeobox contribution to the fusion protein is clearly involved 
in its DNA binding. Ingenuity Pathways Analysis (IPA, http://www.ingenuity.com) allowed us to 
demonstrate that HOXA9 target genes are mostly involved in cell cycle, leukemia and 
hematopoiesis (Figure 15B) and that the location of the sites has a very similar distribution to 
those of NH, which would also correspond mainly to enhancer regions, consistently with 
previous results46 (Figure 15C). 
Importantly, we assessed the ChIP-seq of NUP98 wt, only 17 target genes were identified as 
direct genomic targets of the protein (Anexo table 1).  Strikingly, all of them appeared to have a 
directly role in either leukemogenesis or hematopoiesis (Figure 15D). In addition, analyzing the 
location of the binding regions, we observed that the possible modulatory effect of NUP98 wt on 
gene transcription would be leading primarily by binding to promoters, since half of the regions 
are located between 0 and 1 kb upstream of the TSS of the possible target genes and the other 
half to more than 5 kb (Figure 15E).  
To go a step further into this possible role of NUP98 in hematopoietic differentiation, we 
generated a hHP cellular model that overexpress NUP98 wt (hHP-NUP98) and demonstrated that 
most of the selected candidate targets were upregulated. Interestingly, NUP98 wt was also able 
to induce the downregulation of BIRC3, a well known tumor suppressor gene (Figure 16A). We 
then performed a common Colony Forming Unit (CFU) Assay to compare the ability of 
differentiation and proliferation of the hHP-NUP98 cells with the hHP-empty vector model. CFU 
assay is an in vitro assay based on the ability of hematopoietic progenitors to proliferate and 
differentiate into colonies in a semi-solid media in response to cytokine stimulation. The colonies 
formed can be counted and characterized according to their unique morphology. We importantly 
showed a highly significant increase in colony formation of all types (CFU-G, CFU-GM, BFU-E, 
CFU-M and CFU-GEMM) in hHP-NUP98 (Figure 16B and 16C).  These results lead us to validate 
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the function of NUP98 wt in hematopoiesis and think about a possible oncogenic role in 
hematological malignancies, which would need to be further studied.  
 
 
 
 
 
 
 
 
Figure 15: Identification of HOXA9 and NUP98 wt genomic binding regions. (A) Representation of the 
pMSCV-NUP98 and pMSCV-HOXA9 retroviral vectors. (B) Plot that represents the main functions of the HOXA9 wt 
target genes (IPA output) (C) Plot that represents the localization of NUP98 wt binding sites in distance (Kb) from the 
TSS. (D) Plot that represents the main functions of the NUP98 wt target genes (IPA output) (D) Plot that represents 
the localization of NUP98 wt binding sites in distance (Kb) from the TSS. 
0 10 20 30 40 50 
Cell Cycle 
Differentiation of leukemia cell lines 
Contact growth inhibition of leukemia … 
Activation of cytarabine 
Replication of Herpesviridae 
Hematopoiesis of leukemia cell lines 
Nº of genes 
Top functions and diseases of Hoxa9 target genes 
0 
5 
10 
15 
20 
25 
-5
 -
 -
3
 K
b
 
-3
 -
 -
1
 K
b
 
-1
 -
 0
 K
b
 
0
 -
 1
 K
b
 
1
 -
 3
 K
b
 
3
 -
 5
 K
b
 
%
 B
in
d
in
g 
si
te
s 
Distance from TSS 
Location of Hoxa9 
binding sites 
0 1 2 3 4 5 
Cell death of tumor cell lines 
Proliferation of tumor cell lines 
Apoptosis of leukemia cell lines 
Differentiation of leukemia cell lines 
Phagocytosis of leukemia cell lines 
Quantity of Ca2+ 
Phosphorylation of protein 
Activation of leukemia cell lines 
Nº of genes 
Top functions and diseases of Nup98 target genes 
0 
10 
20 
30 
40 
50 
60 
> 
- 
5
 k
b
 
-3
 -
 -
1
 K
b
 
0
 -
 1
 K
b
 
3
 -
 5
 K
b
 
%
 B
in
d
in
g 
si
te
s 
Distance from TSS 
Location of Nup98 
binding sites 
A 
B C 
D E 
82 
 
  
 
 
 
 
Figure 16: Nup98 plays a role in hematopoiesis. (A) Expression analysis by qRT-PCR for the eight selected 
NUP98 wt target genes in the hHP-NUP98 cellular model. The expression of the endogenous human housekeeping 
gene GAPDH was used to normalize the data and they are expressed as the mean of 2
-ΔCt
 values obtained for each 
sample after normalization with hHP-empty vector model. Error bars represent SEM.  (B) Colony-forming assay with 
hHP-NUP98 cells and hHP-emtpy vector cells. Average number of colonies per dish from 2 independent experiments 
after 10 days are shown (only colonies with > 50 cells/colony were counted). Error bars represent SEM. (C) 
Microscopy images of the different types of colonies identified in the hHP-Nup98 cellular model CFU assay: CFU-G 
(Colony forming unit-granulocyte), CFU-GM (Colony forming unit-granulocyte, macrophage), BFU-E (Burst forming 
unit-erythorid), CFU-M (Colony forming unit-macrophage) and CFU-GEMM (Colony forming unit-granulocyte, 
erythrocyte, macrophage, megakaryocyte)  
C 
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4 NUP98-HOXA9 target genes analysis 
 
Our next step was to focus on the study of the identify NH target genes and try to find some 
molecular mechanism that may explain, at least partially, its effect on leukemogenesis. When we 
analyzed this set of target genes using Ingenuity Pathways Analysis, we found enrichment in 
functions such as survival, cell cycle, leukemia and development and function of the hematologic 
system (Figure 17A). Among these genes, we found oncogenes implicated in the development of 
leukemia, but also interesting tumor suppressor genes such as NF1, PTEN or BIRC3. 
Furthermore, regarding the canonical pathways associated to NH, only Protein kinase A 
signaling were found significantly enriched, whereas we found that most of the genes were 
involved in a wide range of different molecular pathways. In light of these data, we conclude that 
the target genes of NH are involved on different molecular pathways but targeting the same 
biological functions. 
Importantly, we validated, in the human hematopoietic progenitor model (hHP-NH), the 
DNA direct binding of NH to the regulatory regions of the eight leukemic target genes that we 
selected before (Figure 17B), meaning that the ChIP-seq results can be perfectly extrapolated 
from the cellular model with 293FT cell line to the human hematopoietic progenitor model. 
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Figure 17: NUP98-HOXA9 target genes. (A) Plot that represents the main functions of the NH target genes 
(IPA output) (B) qChIP fold enrichment of NH in hHP-NH cellular model and hHP in the eight selected regions. The 
average of 3 experiments is shown. Error bars represent standard error of the mean (SEM). (C) PolII qChIP fold 
enrichment on the eight selected NH target regions. Average of 3 experiments is shown. qChIP fold enrichment of 
NH in hHP-NH cellular model and hHP in the eight selected regions. The average of 3 experiments is shown. Error 
bars represent standard error of the mean (SEM). 
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4.1 HOXA9-PBX3-MEIS axis 
The ChIP-seq data demonstrated that PBX3 and HOXA9 are both common targets of the 
fusion protein as well as of the wild type NUP98 (Figure 14A). In addition, we also found that 
both the fusion protein and HOXA9 bind to the regulatory regions of MEIS1. These three 
transcription factors, PBX3, HOXA9 and MEIS1, form an activator complex that regulates the 
expression of genes involved in the AML induction26,47,48,88,89. Accordingly, we showed the 
significantly overexpression of these three genes in the hHP-NH cellular model, when comparing 
the hHP transducted with the empty vector (Figure 18A).  
To determine whether NH has a direct involvement in the deregulation of PBX3, HOXA9 and 
MEIS1, we subcloned their identified enhancer regions upsetream to the luciferase gene. For the 
three regions, we observed a significant increase in the luciferase activity when NH was also 
expressed (Figure 18B) demonstrating that NH directly induces the overexpression of the three 
target genes by binding to their enhancer regions. Remarkably, the findings were observed also 
in primary samples of three patients bearing the fusion gene, where we also showed the 
overexpression of these target genes (Figure 18C) 
From the ChIP-seq analysis of NH, we also found that the fusion gene binds to the regulatory 
regions of three hsa-miR-181 family members (hsa-miR-181a1, hsa-miR-181a2 and hsa-miR-
181b).  PBX3 and HOXA9 are potential targets of the miR-181 family (particularly, miR-181b). In 
our hHP-NH cellular model, we observed a significant downregulation (Figure 18D) of miR-181b, 
most likely contributing to greater overexpression of the HOX/PBX3 signature.  
All together, these data highlighted the important role of these three target genes in the 
oncogenic process induced by NH. 
Thus, given the potential relevance of the HOXA9-PBX3-MEIS1 axis, we assessed the 
molecular interactions between PBX3, HOXA9 and MEIS1, and their relationship with the 
chimeric NH protein. We generated a new cellular model from 293FT cells by co-expressing NH 
and HOXA9 and performed different co-immunoprecipitation studies (Co-IPs). We demonstrated 
that HOXA9 forms a stable heterocomplex with the PBX3 and MEIS1 proteins (Figure 19A). 
Furthermore, among the known target genes of MEIS1-HOXA9-PBX3, we selected MYB, MEF2C 
and FLT3 and demonstrated that the complex was sufficiently functional to overexpress them in 
the hHP-NH cellular model (Figure 18E). 
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Figure 18: HOXA9-PBX3-MEIS axis.  (A) Expression analysis by qRT-PCR of MEIS1, HOXA9 and PBX3 in the hHP-NH 
cellular model. The expression of the endogenous human housekeeping gene GAPDH was used to normalize the 
data and they are expressed as the mean of 2
-ΔCt
 values obtained for each sample after normalization with hHP-
empty vector model. Error bars represent SEM. (B) Luciferase assay to evaluate the activity of NH on the enhancers 
of MEIS1, HOXA9 and PBX3. Data are presented as mean from two separate experiments with n=3 for each 
experiment. Error bars represent SEM. (C) Expression analysis by qRT-PCR that showed the overexpression of MEIS1, 
HOXA9 and PBX3 in three primary samples of patients with t(7;11)(p15;p15). Error bars represent SEM.  (D) 
Expression analysis by qRT-PCR that showed the downregulation of has-miR181b in hHP-NH model compared to the 
hHP-empty vector. Data were normalized on the expression of the artificial Homo sapiens miRNA control RNU19. (E) 
Expression analysis by qRT-PCR of MYB, MEF2C and FLT3 in the hHP-NH cellular model. 
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4.1.1 Interaction between NUP98-HOXA9 and PBX3  
 
The chimeric NUP98-HOXA9 retains the short ANWL motif of HOXA9, which binds the PBX 
family, but the MEIS1 interaction domain is lost 26. Consistent with this, we demonstrated that 
NH was indeed able to interact with the complex through PBX3 but not through MEIS1 by 
performing co-immunoprecipitations in the 293FT cellular model (Figure 19A). We scanned the 
DNA target sequences of NH for the HOXA9-MEIS1-PBX binding motif (ATGATTTATGGC48) and 
found 1981 co-occurrences with p ≤ 0.0001 using FIMO (Table S2) suggesting a strong 
cooperation between NH and the complex itself in inducing the final transcriptional profile.  
NH could recruit the HOXA9-PBX3-MEIS1 complex through PBX3 and direct it to its own 
regulatory target regions. However, it has been shown that the complex co-occupies cellular 
promoters that drive leukemogenesis90; therefore, the loop that communicates enhancers with 
promoters could enable the binding of the complex to the promoters of the same genes thanks 
to the interaction with NH. 
 To investigate this aspect, we cloned the coding region of PBX3 fused to FLAG-tag (Figure 
19B) and the coding region of NH without any tag in the retroviral vector. We generated a new 
cellular model with these vectors by co-transfecting 293FT cells and performed two distinct 
qChIP approaches. On one hand, we analyzed the PBX3 enrichment in the same regulatory NH 
target regions and we observed that PBX3 is only binding to the enhancers of MEIS1, MET, BRAF 
and NF1 in the presence of NH and not interact to any of the enhancers whether NH is not 
expressed (Figure 19C). Likewise, we observed that PBX3 is not binding to any promoter neither 
in the absence nor presence of the fusion protein (Figure 19D).  
In the light of these results, we could conclude that the interaction of NH with the complex 
seems not to be crucial to its oncogenic functions. 
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Figure 19: Interaction of NUP98-HOXA9 with PBX3. (A) Analysis of NH and MEIS1-HOXA9-PBX3 complex 
interactions by co-immunoprecipitation. Input lysates and immunoprecipitated proteins were analyze by 
immunoblotting using anti-FLAG antibody. α-tubulin protein levels were used as load control (B) Representation of 
the pMSCV-PBX3 retroviral vector. (C-D) PBX3 (anti-FLAG) qChIP fold enrichment on the eight selected target genes: 
enahcers (C) and promoters (D). Error bars represent standard error of the mean (SEM). 
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4.1.2 Chemical disruption of the HOXA9-PBX3-MEIS complex 
We next decided to evaluate the biological relevance of this oncogenic axis in the NH-AML 
context using the HXR9 peptide that works as a specific inhibitor of the HOXA9-PBX interactions. 
HXR9 is an 18-amino-acid peptide that harbors the hexapeptide sequence of HOXA9 that can 
bind to PBX3 and 9 C-terminal arginine residues (R9) that facilitate cell entry47. This peptide 
seems to have high therapeutic potential in several tumor types including cytogenetically 
abnormal AML (CA-AML) that overexpresses HOX-PBX signature47,91,92. We evaluated the 
sensitivity to HXR9 of our hHP-NH model.  Sorted cells were plated in triplicate with titrating 
doses of the drug to obtain the median Lethal Dose (LC50, is the dose required to kill half of the 
cells after 24 hours of treatment) that was 13μM. Supporting our hypothesis, we observed an 
inhibitory effect on cell viability (30%) after 13μM HXR9 treatment at different time points. 
(Figure 20A).  As control, we used the treatment with the peptide CXR9 that lacks a functional 
hexapeptide sequence but includes de R9 sequence.  Furthermore, we also treated hHP-NH 
colony forming cells with 13μM HXR9 and observed a significant decrease in the number and the 
size of the colonies compared with cells treated with the control peptide. This response seemed 
to be conditioned by the presence of the chimeric protein since it was not observed when we 
treated wild type human hematopoietic cells (hHP) (Figure 20B and 20C). Apoptotic cells were 
identified using flow cytometry and APC-labeled anti-annexin V antibody. Consistently, an 
increase in apoptosis was observed when cells were treated with 13μM and 30μM HXR9 for 24 
hours compared with controls (Figure 20D). 
These results showed the role of NH in the activation of the HOXA9-PBX3-MEIS1 axis and 
provided evidence for its actionability as a new therapeutic approach for this leukemia. 
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Figure 20: Chemical disruption of the HOXA9-PBX3-MEIS complex. (A) Analysis of the response to HXR9 
treatment. hHP-NH cells were exposed to 13uM of HXR9/CXR9 and cell viability was assessed at different time points 
using WST-1. Averaged normalized optical density (OD) values of three independent experiments are shown. (B) 
Colony-forming assay with hHP-NH cells and hHP-emtpy vector cells treated with 13uM HXR9/CXR9. Average 
number of colonies per dish from 2 independent experiments after 10 days are shown (only colonies with > 50 
cells/colony were counted). Error bars represent SEM. (C) Morphology of colonies of hHP-NH treated cells.  (D) hHP-
NH and hHP-empty vector cell apoptosis assay after the treatment with 13 uM and 30uM of HXR9 peptide for 24 
hours. Cells were stained with annexin V and analyzed using flow cytometry. The plot shows the averaged fold 
changes of 3 independent experiments compared to CXR9 (30uM). Error bars represent SEM. 
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4.2 Effect of NUP98-HOXA9 on its other target genes 
To gain insight into the molecular mechanisms that could explain the global expression 
profiling of this oncogenic model, we performed gene expression analysis of three independent 
clones of hHP-NH (Table S5) and three independent clones of hHP-empty vecto were used as 
control. From previous studies, only a subset of these data is publically available 27,53-55  and the 
most salient feature of these clones was a preponderance of upregulated genes. However, we 
did not want to focus our study on analyzing the genes up or down-regulated in the hHP-NH 
model since it has already been discussed before, but understand the effect of NH in the 
regulation of gene expression. Thus, we wanted to discover what was happening with the target 
genes of the fusion protein and applying GSEA analysis to our expression profile data, we found 
that NH seemed to induce overexpression and down-regulation of its target genes, previously 
identified in the ChIP-seq experiments (Figure 21A).   
Since the chimeric protein retains the FG repeat domain of NUP98, NH may interact with 
different transcriptional regulatory cofactors, including the known activator p300 and the 
inhibitor HDAC1. To demonstrate that the activator-repressor role of NH may rely on these 
interactions, we assessed their potential influence on global gene regulation in our human 
cellular model. As expected, the Co-IPs performed in 293FT cellular models demonstrated the 
direct interactions of NH with both p300 and HDAC1 (Figure 21B).  
We then used expression data to assess the role of these interactions in the transcriptional 
regulation driven by NH. We selected eight target genes, four (MEIS1, HOXA9, PBX3 and AFF3) 
that were upregulated in the hHP-NH model and four (BIRC3, SMAD1, FILIP1L and PTEN) that 
were downregulated. We then designed primers to analyze the occupancy of their promoters by 
performing different qChIP assays. We found that p300 bound to the promoters of the 
overexpressed genes only when NH was present. On the other hand, we also observed an 
enrichment of HDAC1 within the promoter regions of the downregulated genes when the fusion 
protein was present, thereby demonstrating its hypothesised dual role (Figures 21C and 21D).  
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Figure 21: Effect of NUP98-HOXA9 on its other target genes. (A) GSEA plots using the NHChIP-seq gene set 
and the expression array data from hHP-NH cellular. (B) Analysis of NH and p300/HDAC1 interactions by co-
immunoprecipitation. HEK293FT cells were transfected with pMSCV-Nup98-Hoxa9 or pMSCV-empty vectors. 48h 
post-transfection, the immunoprecitpitation was performed by using anti-p300 and anti-HDAC1 antibodies. Proteins 
were analyze by immunoblotting using anti-FLAG antibody. GAPDH protein levels were used as load control. (C) 
qChIP fold enrichment of p300 and HDAC1 in the regulatory regions of four upregulated and four downregulated 
target genes of NH in 293FT cellular models. The average of 3 experiments is shown. Error bars represent SEM.  
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5 In vitro analysis of the efficacy of the HDAC inhibitors on 
hHP- NUP98-HOXA9 cellular model 
The interaction of NH with HDAC1 and its presence in the promoter of down-regulated 
genes prompted us to evaluate the effectiveness of a treatment with HDACs inhibitors (HDACi). 
HDACi are giving very promising results in the treatment of different hematologic malignancies, 
but to date they have not been studied for patients with the t(7;11)(p15,p15) translocation. 
Thus, we analyzed the sensitivity of our cellular model to the pan-HDACi Panobinostat (LBH589) 
compared with the sensitivity of other AML fusion genes for which the efficacy of this drug has 
already been demonstrated (MLL-AF9 and AML1-ETO). We observed a dramatic inhibitory effect 
that, unexpectedly, was much higher (LC50hHP-NH≈4nM) than that the one observed in the other 
leukemic models of hHP, hHP-MLL-AF9 (LC50hHP-MLL_AF9≈30nM) and hHP-AML1-ETO (LC50hHP-
AML1_ETO≈200nM) fusion genes (Figure 22A). Indeed, the treatment with low doses (4nM) of 
LBH589 completely abrogated the hHP-NH cells capability to form colonies in the CFU assay 
(Figure 22B). Further, hHP-NH cells treated with 4nM and 30nM doses of LBH589 underwent 
apoptosis within 24h, whereas the same concentration of drug had no effect in the hHP-empty 
vector model (Figure 22C).  
Summarizing, these experiments demonstrated that (1) the chimeric protein is capable of 
inducing a deep change in the expression profile (both activating and repressing target genes and 
(2) the repressing activity carried with collaboration of HDAC proteins clearly make those cells 
that harbor the fusion gene extremely sensitive to the treatment with epigenetic inhibitors.  
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Figure 22: Treatment with HDAC inhibitors (A) hHP-NH cells were exposed for 72 hours to serial dilutions 
of panobinostat (LBH589) followed by addition of WST-1 to analyze cell viability. Averaged normalized optical 
density (OD) values are shown compared to vehicle. (B) Colony-forming assay with hHP-NH cells and hHP-emtpy 
vector cells treated with 4nM LBH589. Average number of colonies per dish from 2 independent experiments after 
10 days is shown (only colonies with > 50 cells/colony were counted). Error bars represent SEM. (C) hHP-NH and 
hHP-empty vector cell apoptosis assay after the treatment with 4 nM and 30nM of HXR9 peptide for 24 hours. Cells 
were stained with annexin V and analyzed using flow cytometry. The plot shows the averaged fold changes of 3 
independent experiments compared to vehicle.  Error bars represent SEM. (D) GSEA plots using the NH ChIP-seq 
gene set and the expression array data from NH primary samples. 
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6 Patients with t(7;11)(p15;p15) 
We obtained RNA samples from a further five patients with t(7;11)(p15,p15).  To explore 
the activator-repressor role of NH in primary samples, we performed expression arrays with 
these samples and analyzed the data using GSEA (Table S6). We used three independent clones 
of hHP wt as control. Importantly, we found that the identify target genes behave similarly in 
primary samples and in the hHP-NH cellular model (Figure 22D). We showed both overexpressed 
and down-regulated target genes, thereby validating our finding that the fusion gene plays a dual 
role in transcriptional regulation. 
Moreover, we used single-sample gene set enrichment analysis (ssGSEA) to assess gene set 
activation scores for the five tumor samples. ssGSEA is a rank-based comparison of the 
expression levels of genes in the gene set with all other genes in an expression profile93. In this 
analysis we included different gene sets and analysed the five expression profiles separately. The 
obtained pattern reflects a high level of homogeneity between samples and controls, but we 
observed two distinct clusters, meaning that the expression profiles of NH primary samples 
cluster together. Interestingly, one of the differentially expressed gene sets between patients 
and controls was the NOTCH pathway genes. 
 
 
7 NUP98-HOXA9 binding-proteins identification by Mass 
Spectrometry 
 
NH-interacting proteins have been tried to be identified by traditional yeast two-hybrid 
assays and it has allowed to find some proteins, like the Amino-terminal Enhancer of Split (AES) 
which collaborates with NH in the in deregulating transcription and proliferation60.  However, 
Mass spectrometry is rapidly maturing as a powerful tool for proteomic analysis and specifically 
for the identification of protein-protein interaction. Therefore, in this study, we sought to 
identify and compare proteins that interact with NH, HOXA9 wt and NUP98 wt, using a Mass 
spectrometry assay. 
We used the 293FT-NH, 293FT-HOXA9 and 293FT-NUP98 models to conduct the 
corresponding immunopreticiptations, followed by mass spectrometry. For each model, all 
peptides that appeared at least once in the controls were excluded and we selected only those 
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that appeared in all the three biological replicates analyzed. Table S7 (A-F) contain the lists of the 
proteins identified during these analyses, that interact with NH, HOXA9 or NUP98, respectively. 
 As it is observed in Figure 23, we found a total of 88 NH interacting-proteins, 198 for HOXA9 
and 52 for NUP98. Interestingly, there are 38 proteins that only bind to NH, suggesting that the 
fusion protein acquires a new spatial conformation that allows it to interact with some proteins 
that are not able to bind to neither HOXA9 wt nor NUP98 wt (Figure 24A , Table S7A). Among 
them, we found proteins involved in chromatin remodeling (SMARCD2 or ARID1A), cytoskeletal 
reorganization (ABI1, ABI2, NCKAP1 or CYFIP1) or leukemogenesis (PBX2). However, the most 
striking finding was that NH binds to almost all of the components of the Ccr4-Not complex: 
CNOT1, CNOT3, CNOT6L, CNOT7, CNOT8, CNOT10 and RQCD1. 
 
Figure 23: Mass spectrometry results. Venn diagrams of the overlapping NH, HOXA9 and NUP98 
interacting -proteins indentified with the Mass Spectrometry approach on HEK293F human models 
 
Among the binding proteins that are common to NH and HOXA9 (Table S7D), we found 
proteins responsible of the DNA repair (RPA3, RPA2, RAD18 or SMC3) and cell cycle regulators 
(CDKN2A or SP3). However, again, we made a surprising discovery: both HOXA9 and NH were 
able to interact to all of the members of the COP9 signalosome (GPS1, COPS2, COPS4, COPS5, 
COPS6, COPS7A, COPS7B and COPS8), that is involved in the ubiquitin–proteasome pathway 
(Figure 24B, Table S7D).  We found four proteins that interact with both NH and NUP98 wt 
(Figure 24C, Table S7E). Notably, two of these proteins are RNA splicing regulators (SFRS8 and 
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PNN94), which supports the importance that aberrant splicing is acquiring in the pathogenesis of 
AML95. On the other hand, OGT is a glycosyltransferase that forms a core complex with HCF-1 
and BAP1 that can differentially recruit histone-modifying enzymes to regulate gene expression 
and thereby preserve normal hematopoiesis96. The latter protein of this group, but no less 
interesting, would be PFDN5 or MM1. It is a subunit of prefoldin, a molecular chaperone complex 
that binds and stabilizes newly synthesized polypeptides.  
Finally, among the five interacting proteins that are common to the three entities, the 
presence of HDAC1 and HDAC2 is remarkable since it validates the use of HDAC inhibitors for the 
treatment of patients harboring the NUP98-HOXA9 fusion protein (Figure 24D, Table S7F).   
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Figure 24: Identification of interacting-proteins. (A-D) STRING 9.1 diagrams of the interacting-proteins 
indentified with the Mass Spectrometry.  
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NUP98-HOXA9-associated AML is one of the most aggressive forms of leukemia. It is highly 
refractory to intensive treatment and has a dismal prognosis, only 2-5% of patients surviving in 
five-years. The molecular mechanisms underlying the occurrence of this fusion protein are poorly 
understood. Advancing knowledge in this area could trigger the identification of new and more 
efficient therapeutic targets. The present work provides proof of concept to explore a better 
designed targeted therapy for these patients. 
 
NUP98-HOXA9 genomic binding sites 
By identifying its DNA binding sites, we have shown that the transcription factor activity of 
NH is carried out mainly through enhancers. Each of the eight selected region was characterized 
as enhancer by detecting the enrichment of the H3K4me1 epigenetic mark. We also observed an 
increase in the presence of PolII in seven of the eight target sites when NH is present, indicating 
that the fusion protein could induce the activation of its target enhancers somehow. Moreover, 
through two different in silico analysis of the binding sequences, MEME-ChIP and oOPOSSUM, we 
were able to identify DNA binding motifs of several enhancer pioneer transcription factors (FOX 
proteins and GATA1) in the same target regions of NH. Transcriptional regulation carried out by 
HOXA9 wt is known to be mostly mediated by its binding to enhancers. Our results, therefore, 
prompted us to suggest that the NH binding to DNA is most likely driven by the HOXA9 moiety. 
Indeed, we found that one third of the NH target genes were common to HOXA9 wt.  
Interestingly, a detailed study of the DNA binding regions allowed us to identify a consensus 
sequence (CA/gTTT) that is present in one-third of genomic regions where NH is bound, but is not 
associated with any known transcription factor. This specificity represents a unique and 
promising finding to be further explored.  
 
Unexpected role of NUP98 in hematopoiesis 
Notably, this effect depends not only on the presence of the HOXA9 homeodomain in the 
fusion, but also on the contribution of the NUP98 moiety to the chimeric protein. We have 
shown that this moiety also participates in the interaction of the fusion protein with DNA in a 
human cellular context. An unexpected finding was that not only  the nucleoporin NUP98 
showed direct DNA binding activity, but also that many of the genes involved in the interaction 
play a role in the regulation and differentiation of hematopoiesis. Recent studies have suggested 
that NUP98 acts as a transcription factor in a tissue and status dependent way35. We have 
demonstrated that its overexpression in hHP induces the upregulation of important genes such 
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as HOXA9, PBX3, HOXA7, RARA and PML, but also the downregulation of the tumor suppressor 
gene BIRC3. This role of NUP98 as a hematopoietic transcription factor needs to be further 
explored as it could open the door to important insights into hematopoiesis and leukemia. This 
finding indirectly provides an explanation to why a nucleoporin, mainly though as a structural 
protein, is so commonly rearranged in AML; it has more than 20 different partners that result in 
chimeric proteins with leukemogenic features. This proposed role of NUP98 led us to speculate 
that the loss of one wt allele of the gene, as a consequence of the chromosomal translocation, 
could have some effect on the blockage of hematopoietic differentiation, a common feature of 
myeloid leukemias. Supporting this hypothesis, it has been reported that endogenous NUP98 
interacts with NH in the leukemic cells51, an alternative mechanism that would block the 
transcription factor activity of the nucleoporin. Further, that haploinsuficiency of the NUP98 wt 
was required to induce full leukemic transformation could explain why a complete leukemic 
transformation has not been demonstrated in a retroviral model overexpressing NUP98-HOXA9 
in hHP, where the two wt alleles are intact 54. As we have recently published for other fusion 
genes97, genetically engineered cell models that generate the chromosomal translocation inside 
the cell should provide a more appropriate tool to evaluate this hypothesis. 
 
MESI1-HOXA9-PBX3 axis deregulation 
It is interesting to note some clinical similarities found between NUP98-HOXA9 and MLL 
gene rearrangements that are also events associated with aggressive myeloid leukemias. In both 
cases, it has been observed that there is an induction of erythroid hyperplasia, an abnormal 
erythroid maturation and a similar in vitro mode of transformation27. These findings suggested 
that both chromosomal rearrangements might be sharing some oncogenic mechanisms. 
Accordingly, we found that NH directly induces the overexpression of the three best known 
target genes of MLL-AF9 and MLL-AF447,98,99fusion proteins: MEIS1, HOXA9 and PBX3. These 
three transcription factors can form a transcriptional activator heterocomplex that regulates 
genes involved in the development of AML47,48. Additionally, it has been recently shown that the 
overexpression of a 4-homeobox-gene signature (composed of PBX3, HOXA9, HOXA7 and 
HOXA11) is an independent predictor of poor overall survival in patients with cytogenetically 
abnormal AML (CA-AML)89.  
We demonstrated that the interaction of NH with the specific enhancers of MEIS1, HOXA9 
and PBX3 directly induces their overexpression. In addition, we validated the formation of the 
actively functional heterocomplex MEIS1-HOXA9-PBX3 in cells expressing the fusion protein, 
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since it is able to induce its specific expression signature. Interestingly, we showed that NH could 
interact with this complex through PBX3. However, it seems that PBX3 could be collaborating 
with NH in transcriptional regulation of only a few genes. Therefore, these results suggest that 
recruitment of the complex by NH could be a mechanistic artifact that is not relevant for the NH 
function as transcriptional regulator. This matches previous studies that suggested that Pbx-
interaction motif is not required for the oncogenic mechanism induced by NH26.  
Since Morgan et al.100 designed the peptide HXR9, which is able to disrupt HOXA9-PBX 
interactions and shows effective anti-tumor effects in melanoma models and other solid 
tumors91,92, recent results suggest that HXR9 could improve the survival of the leukemia patients 
with increased expression of the HOXA/PBX3 signature, as is the case for MLL-rearranged 
leukemia47. The role of PBX proteins, HOXA9 and MEIS1 in the context of NUP98-HOXA9 
leukemia has been previously discussed26, but with these new findings, a revision of their 
function in this context was required. Thus, we evaluated the efficacy of HXR9 treatment in our 
hHP-NH model and observed a clear inhibitory effect on cell viability. This effect is not as 
dramatic as in other leukemic fusions studied previously47, indicating that the deregulation of the 
PBX3-HOXA9-MEIS1 axis is probably not the only driver determining the transformative power of 
NH. 
 
Target miRNAs of NUP98-HOXA9 
Among the 17 target miRNAs of NH that we identified in the ChIP-seq analysis (Table 3), we 
found three miR181 family members:hsa-miR-181a1, hsa-miR-181a2 and hsa-miR-181b. It has 
been shown that the miR181 family acts as a regulator of myeloid differentiation101 and that its 
downregulation contributes to the poor prognosis of cytogenetically abnormal AML patients89. 
Interestingly, PBX3, HOXA9, HOXA7 and HOXA11 are potential targets of the miR-181 family 
(particularly, miR-181b). In our hHP-NH cellular model we also observed the significant 
downregulation (Figure 9) of miR-181b which clearly entails an additional mechanism of the 
fusion protein to obtain an even greater overexpression HOX/PBX3 signature. Another miRNA 
that could be regulated by NH is hsa-miR-128, which targets the expression of genes NF1102, MLL 
and AF4103, all of them with an important role in human leukemia. NF1 is a tumor suppressor 
gene whose downregulation is a common event in AML104. On the other hand, MLL is frequently 
involved in chromosomal translocations in aggressive human lymphoid and myeloid leukemias. 
One of these MLL-associated leukemias results from a balanced translocation between MLL and 
AF4. hsa-miR-128 is able to downregulate the expression of MLL, AF4, and both MLL-AF4 and 
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AF4-MLL fusion genes103. The data suggests that the deregulation of this miRNA by NH could 
serve an important function in the development of the leukemia. Finally, hsa-miR-30A has been 
proposed as a tumor suppressor gene in CML that is also deregulated by BCR-ABL105. 
 
Other NUP98-HOXA9 target genes 
Although this work has focused specifically on three of the target genes of NH for their key 
role in AML (MEIS1, HOXA9 and PBX3), the rest must not be ignored. Here, we summarize the 
most relevant features of the selected target genes and their relation to AML and other 
hematological cancers: 
- MET is an oncogene that acts as receptor tyrosine kinase. A recurrent activating mutation 
in MET that is  also described in small cell lung cancer and breast cancer, has been found in 
AML106. MET signaling is a requisite pathway in the growth and survival of AML cells in nearly half 
of the primary clinical samples107. 
- BRAF is a serine/threonine protein kinase involved in cell division, differentiation, and 
secretion.  Mutations in this gene have also been associated with various types of cancer. In 
AML, BRAF mutations, as well as other mutations of genes more downstream in the RAS-BRAF 
pathway, are very frequent108. 
- AF9 is a member of the YEATS domain superfamily with functions in transcriptional 
elongation. AF9 is one of the most common translocation partners of MLL fusion proteins that 
are responsible for a subset of acute leukemias. It has been proposed as an attractive 
pharmacological target in such diseases109. 
- NF1 is a tumor suppressor gene that negatively regulates the RAS signal transduction 
pathway and, as discussed above, it appears mutated or deleted very frequently in AML110. 
- PTEN is another tumor suppressor gene that is inactivated in many human cancers, 
including AML and other hematological malignancies111. PTEN is a negative regulator of AKT/PKB 
signaling pathway. 
- AFF3 is a nuclear transcription factor that may function in lymphoid development and 
oncogenesis. It has been found in fusion with MLL in acute lymphoblastic leukemia patients112. 
- BIRC3 negatively regulates MAP3K14, an activator of the non-canonical pathway of NF-κB 
signalling. This gene is frequently mutated and deleted in Chronic Lymphocytic Leukemia (CLL).  
CLLs harbouring BIRC3 disruption display constitutive NF-κB activation that is associates with 
unfavorable clinical and genetic features and predicts poor outcomes independent of other risk 
factors113. 
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- SMAD1 belongs to the SMAD family and it is a signal transducer and a transcriptional 
modulator that mediate multiple signalling pathways involved in a range of biological activities 
including cell growth, apoptosis, morphogenesis, development and immune responses. Smad-
signalling circuitry is intimately linked to normal and leukemic hematopoiesis114.  
- FILIP1L is a novel tumor suppressor that inhibits the canonical WNT signalling and has its 
expression downregulated in various cancers. Its great potential as a cancer therapeutic target 
has been proposed.115 
Given the important functions of these genes in tumorigenesis and leukemia development, 
the oncogenic mechanism induced by NH is likely the result of the collaboration of all of them. In 
this regard, we decided to assess the effect of NH on the rest of its target genes, both in our 
model and, more relevantly, in primary samples. We observed that the fusion protein seemed to 
have the capacity to induce both upregulation and downregulation. This result confirms that the 
preponderance of overexpressed genes described the hHP-NH signatures27,54,55 is most probably 
due to a downstream effect (for example, gene activation induced by PBX3-HOXA9-MEIS1), 
rather than the direct action of NH. 
In order to better understand this activator-repressor role that NH seems to have on its 
target genes, we explored the capacity of the Nup98 moiety of the fusion protein to recruit 
transcriptional regulators, such as the coactivator p300 or the corepressor HDAC151. We 
demonstrated, for the first time, this dual role, showing the presence, along with the fusion 
protein, of p300 and HDAC1 in the regulatory regions of the overexpressed and downregulated 
NH-target genes, respectively.   
 
Treatment with HDAC inhibitor 
HDAC inhibitors are a novel class of anticancer agents that block the activity of HDACs with 
promising therapeutic expectations in different types of myeloid malignancies. Since in our 
model we identified the involvement a molecular mechanism that justifies the use of these drugs 
in patients harboring the NH fusion protein, we assayed in vitro the potential use of LBH589 
(Panobinostat).  We observed a high inhibitory effect in hHP-NH after treatment with that was 
more efficient in our model than in others myleoid cell lines bearing fusion genes such as MLL-
AF9 or AML1-ETO.   
Likewise, we suggested that a p300 inhibitor like C646, that induces cell cycle arrest and 
apoptosis selectively in AML-ETO positive AML cells116, could also be tested in the cellular models 
and in patients that harbor NH.  
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However, in patients with t(7;11)(p15;p15), we found a stronger presence of downregulated 
target genes, indicating that the treatment with HDAC1 could be even more effective. Patients 
with the translocation should be included in Panobinostat clinical trials.  
Probably the best therapeutic option for these patients would be the use of combination 
therapies that include the proposals made in this study.  
 
New NUP98-HOXA9 interacting-proteins 
The Mass spectrometry results confirm that NH is not only an aberrant transcription factor 
but that its ability to interact with many other proteins allows it to expand its leukemogenic 
potential to achieve the high degree of malignancy that characterizes it.  We found that NH binds 
to almost all the components of the CCR4-NOT complex and that this capacity could be acquired 
from the specific spatial conformation of the fusion protein, since none of the proteins of the 
complex seem to interact neither with NUP98 wt norHOXA9 wt. The CCR4-NOT complex is a 
unique, essential and conserved multi-subunit complex117. It has been studied mostly in 
Saccharomyces cerevisiae but the orthologous genes have been found in humans. The complex is 
composed by two functional modules with different subunits that comprise two different 
enzymatic activities: deadenylation and ubiquitination. The combination of these two activities 
allows coordinating multiple functions such as mRNA degradation, protein synthesis and 
degradation, RNA nuclear export and chromatin modification. In this broad range of processes, it 
has a direct involvement in transcriptional regulation or DNA damage response, making it 
essential for cell viability 118. Given these important functions, the newly identified ability of NH 
to interact with the CCR4-NOT complex and its role in leukemogenesis open up an exciting 
research field. 
Another striking finding came up when we identified, among the binding proteins that are 
common to NH and HOXA9, all of the COP9 signalosome components. It is a conserved protein 
complex that operates in the ubiquitin–proteasome pathway.  Although its mechanism of action 
is not yet fully understood, it is rapidly emerging as a key player in the DNA-damage response, 
cell-cycle control and gene expression119. Further studies are necessary to elucidate the 
consequences of the interaction between the fusion protein and the intriguing and 
multifunctional COP9 signalosome in leukemic transformation. Importantly, NH and Hoxa9 also 
bind to MAEA, a key protein in normal differentiation of erythroid cells and macrophages120. As 
NH induces erythroid hyperplasia and abnormal erythroid maturation27, it is very likely that the 
interaction with MAEA plays a role in this process. 
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In addition, we found that NH and NUP98 wt interact with OGT, a protein whose usual role 
in hematopoiesis could be altered because of this interaction, helping in the induction of the 
impaired blood differentiation that is characteristic of NH-driven AML. Regarding the interaction 
between NH and MM1, it is noteworthy that mutations in MM1 are often observed in patients 
with leukemia or lymphoma and it has been considered as a tumor suppressor that acts by 
repressing the transcriptional activity of the proto-oncogene c-Myc87. The interaction with the 
fusion protein could free c-myc, allowing it to carry out its oncogenic activity.                  
Finally, mass spectrometry results let us find out that both HDAC1 and HDAC2 are able to 
interact with NH, HOXA9 and NUP98. It has already been proposed that the retained FG-repeat 
domain of Nup98 in the fusion protein could be mediating the interaction with HDAC137. 
However, the possibility that HOXA9 wt also binds to HDACs had not ever been considered. 
Furthermore, the fact that the fusion protein is also able to recruit HDAC2 supports the 
effectiveness of the treatment with Panobinostat, the tested pan-HDACs inhibitor, in this kind of 
leukemia. 
We have been highly restrictive in the analysis of the MS results, which explains why we 
have not been able to detect some NH interacting-proteins already identified in previous works. 
However, this approach made it possible to find a large number of novel collaborators of the 
fusion protein that would contribute to the discovery of new molecular mechanisms underlying 
this oncogene. Features and architecture of these interactions need to be further explored.  
 
Final remarks 
Our work describes most of the molecular mechanisms that underlay the leukemogenic 
activity of the NH fusion protein. A surprising new function for the nucleoporin NUP98 in 
hematopoiesis has been demonstrated. We have described how NH has the ability to interact 
with HDAC1 and p300 to inhibit and induce gene expression respectively.  
With the evidences on the activation of the PBX3-MEIS1-HOXA9 axis, and the supporting 
data coming from primary samples, we have provided new biological rationales for widening the 
therapeutic reservoir for the patients. 
It is important to note that since it is now clear that the NUP98 moiety plays a crucial role in 
leukemogenesis, other NUP98 fusions could share the same mechanism of action. The proposed 
therapeutic approaches could represent a breakthrough in the treatment of a larger number of 
cases of acute myeloid leukemia. 
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Finally, our description of a huge amount of novel NH interacting-proteins supports the idea 
that NH is not only an aberrant transcription factor, but that its ability to interact with many 
other proteins allows it to expand its leukemogenic potential to achieve the high degree of 
malignancy that characterizes it.   
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CONCLUSIONES 
1. Hemos generado con éxito dos modelos celulares humanos que expresan NUP98-HOXA9 
de forma constitutiva. Uno de ellos se ha generado a partir de células embrionarias 
epiteliales y otro a partir de progenitores hematopoyéticos humanos. Éste último fue 
capaz de reproducir la proliferación aberrante inducida por la proteína de fusión. 
 
2. Nuestro trabajo supone la primera descripción de los sitios de unión al DNA específicos de 
NUP98-HOXA, la mayoría de los cuales son regiones reguladoras “potenciadoras”. Hemos 
identificado un nuevo motivo de unión específico para NUP98-HOXA9 (CA/gTTT) que está 
presente en un tercio de sus sitios diana. NUP98-HOXA9 se une a las regiones reguladoras 
de 1363 genes y 17 microARNs  que están principalmente implicados en procesos de 
muerte celular, supervivencia, ciclo celular y desarrollo de la leucemia. 
3. NUP98-HOXA9 activa directamente la expresión de los genes que forman el complejo 
MEIS1-HOXA9-PBX3 mediante la interacción con sus regiones reguladoras 
“potenciadoras”, constituyendo, esta activación, uno de los mecanismos patogénicos 
inducidos por la proteína de fusión. La desestabilización de este complejo usando el 
péptido HXR9 en progenitores hematopoyéticos humanos que expresan NUP98-HOXA9 
tiene un efecto directo y específico en la viabilidad celular. Este resultado nos lleva a 
proponer al eje MEIS1-HOXA9-PBX3 como una adecuada y prometedora diana 
terapéutica que debe ser evaluada en pacientes con la transclocación t(7;11)(p15;p15). 
4. Al analizar la función cada una de las dos partes que forman la proteína de fusión, 
encontramos que un tercio de los genes diana de NUP98-HOXA9 son comunes a HOXA9 
wt, lo que confirma la importancia del homeodominio en la capacidad de interacción con 
el DNA. Por otro lado, proponemos una papel para NUP98 wt en la regulación 
hematopoyética, ya que identificamos 17 regiones de unión al DNA y todas ellas  parecen 
tener una función en hematopoyesis o leucemogénesis. Además, la sobreexpresión de 
NUP98 wt en progenitores hematopoyéticos humanos activa la expresión de genes diana 
implicados directamente en el desarrollo de la LMA e induce proliferación celular. Estos 
resultados sugieren, por tanto, un papel oncogénico para NUP98 en neoplasias 
hematológicas.  
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5. El análisis de la expresion génica en modelos celulares humanos y muestras primarias de 
pacientes sugieren que NUP98-HOXA9 podría tener un papel activador-represor en la 
regulación transcripcional que estaría determinado por su interacción con p300 
(activador transcripcional) y con HDAC1 (inhibidor transcripcional). 
6. La función represora de la transcripción génica que parece tener NUP98-HOXA9 en 
colaboración con HDACs, hace que las células que expresan el gen de fusión sean 
extremadamente sensibles al tratamiento con el inhibidor de HDAC LBH589 
(Panobinostat). Además, observamos que el efecto de LBH589 es mucho mayor en el 
modelo celular que expresa NUP98-HOXA9 que en otros modelos leucémicos para los que 
la sensibilidad a esta droga ya había sido demostrada. Por tanto, proponemos 
firmemente que los inhibidores de HDAC, solos o en combinación con otros agentes 
quimioterapéuticos, sean probados en pacientes con este tipo de leucemia.  
7. El análisis mediante espectrometría de masas nos ha permitido identificar y comparar un 
gran número de nuevas proteínas que interaccionan con NUP98-HOXA9, HOXA9 and 
NUP98. Estos resultados confirman que la proteína de fusión no es solamente un factor 
de transcripción oncogénico, si no que su capacidad de interacción con otras proteínas le 
permite ampliar su potencial leucemogénico para conseguir el alto grado de malignidad 
que le caracteriza. Sin embargo, la arquitectura y características de estas interacciones 
necesitan ser estudiadas en mayor profundidad.  
8. En conjunto, estos datos indican que el proceso oncogénico inducido por el gen de fusión 
NUP98-HOXA9 implica una enorme variedad de mecanismos moleculares: la regulación 
directa e indirecta de la expresión génica a través de regiones potenciadoras, 
modificaciones epigenéticas y una amplia red de interacciones proteicas. Este escenario 
inducido por la translocación cromosómica puede ser responsable de la compleja biología 
que presentan los progenitores leucémicos y probablemente explica la falta respuesta a 
los tratamientos actuales disponibles para esta enfermedad.  
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CONCLUSIONS 
1. We successfully generated two human cellular models that expressed NUP98-HOXA9 in a 
constitutive manner. One was based on embryonic epithelial cells and the other on 
human hematopoietic progenitors. The latter was able to reproduce the aberrant 
proliferation induced by the fusion protein. 
 
2. Our work provides the first description of the DNA binding sites of NUP98-HOXA9, most 
of which are enhancer regulatory regions. We identify a novel specific motif (CA/gTTT) for 
NH that is present in one-third of its target genomic regions. NH is binding to the 
regulatory region of 1363 genes and 17 miRNAs that are mainly involved in cell death, 
survival, cell cycle and leukemia development.  
3. NUP98-HOXA9 directly activates the expression of the complex MEIS1-HOXA9-PBX3 by 
interacting with its respective enhancers and it constitutes one of the pathogenic 
mechanisms induced by the fusion protein. The disruption of this complex with the HXR9 
peptide in human hematopoietic progenitors that express NUP98-HOXA9 has a direct 
effect on cell viability. This results led us to propose the MEIS1-HOXA9-PBX3 axis as a 
good therapeutic target to evaluate in patients with the t(7;11)(p15,p15).  
4. Analyzing the role of each moiety of the fusion protein, we found that one-third of the NH 
target genes are common to HOXA9 wt, which confirms the importance of the homeobox 
domain in the ability to interact with the DNA. We also propose a function in 
hematological differentiation for the nucleoporin NUP98, since we identified 17 DNA 
binding sites and all of them appeared to play a direct role in hematopoiesis or 
leukemogenesis. In addition, its overexpression in hHP activates the expression of genes 
directly involved in AML development and induces cell proliferation. Therefore, these 
results also suggest an oncogenic role for NUP98 in hematological malignancies  
5. Gene expression analysis in human cellular models and primary samples suggests an 
activator-repressor role to NUP98-HOXA9 in the transcriptional regulation that is 
determined by its interaction with both p300 (transcriptional activator) and HDAC1 
(transcriptional inhibitor).  
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6. The repressing transcriptional activity carried by NH with collaboration of HDAC proteins 
clearly make those cells that harbor the fusion gene extremely sensitive to the treatment 
with the pan-HDAC inhibitor LBH589 (Panobinostat). We found that the inhibitory effect 
of LBS589 was much higher in the cellular model expressing NH than in other leukemic 
models for which the sensitivity to this drug has already been demonstrated.  Thus, we 
strongly proposed that HDAC inhibitors, alone, or in combination with other 
chemotherapeutic agents, must be tested in NH driven AML patients. 
7. Mass Spectrometry allowed us to identify and compare a huge number of novel binding-
proteins of NH, HOXA9 and NUP98. These results confirmed that NH is not only an 
aberrant transcription factor, but that their ability to interact with many other proteins 
enable to expand its leukemogenic potential to achieve the high degree of malignancy 
that characterizes it.  However, the features and architecture of these identified 
interactions need to be further explored. 
8. Taking together, all data indicate that the leukemogenic process induced by fusion gene 
NUP98-HOXA9 involves several molecular mechanisms: direct and indirect gene 
regulation via enhancers, epigenetic modifications and a novel network of protein 
interaction. This profoundly aberrant landscape induced by the translocation may be 
responsible of the complex biology of the leukemic hematopoietic progenitor and 
probably explain the lack of response to the current treatments available for this disease. 
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Supplementary Tables 
 
Table S1: NUP98-HOXA9 target genes identified by ChIP-seq (see data on CD-room) 
 
Table S2: Co-occurrences of HOXA9-MEIS1-PBX binding motif in the DNA target sequences of NH 
(FIMO results) (see data on CD-room) 
 
Table S3: HOXA9 target genes identified by ChIP-seq (see data on CD-room) 
 
Table S4: NUP98 target genes identified by ChIP-seq (see data on CD-room) 
 
Table S5: Expression arrays in cellular models (see data on CD-room) 
 
Table S6: Expression arrays in patients (see data on CD-room) 
 
Table S7: Interacting-proteins indentify by Mass spectrometry assay 
 
A. ONLY Nup98-Hoxa9 INTERACTING-PROTEINS  
CCR4-NOT transcription complex subunit 1  CNOT1 
Isoform 2 of CCR4-NOT transcription complex subunit 1  CNOT1 
CCR4-NOT transcription complex subunit 3  CNOT3 
Nuclear RNA export factor 1  NXF1 
Isoform 2 of CCR4-NOT transcription complex subunit 10  CNOT10 
Cell differentiation protein RCD1 homolog  RQCD1 
Isoform 2 of CCR4-NOT transcription complex subunit 7  CNOT7 
CCR4-NOT transcription complex subunit 11  CNOT11 
Isoform 3 of RalBP1-associated Eps domain-containing protein 1  REPS1 
DNA repair protein XRCC1  XRCC1 
AP-1 complex subunit beta-1 (Fragment)  AP1B1 
AT-rich interactive domain-containing protein 1A  ARID1A 
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha  PIK3C2A 
Isoform 2 of Remodeling and spacing factor 1  RSF1 
Cytoplasmic FMR1-interacting protein 1  CYFIP1 
Chromodomain-helicase-DNA-binding protein 4  CHD4 
Isoform 10 of Abl interactor 1  ABI1 
Uncharacterized protein C10orf88  C10orf88 
BMP-2-inducible protein kinase  BMP2K 
Nck-associated protein 1  NCKAP1 
NTF2-related export protein 1  NXT1 
Metastasis-associated protein MTA2  MTA2 
Abl interactor 2 (Fragment)  ABI2 
Protein Dr1  DR1 
Cyclin-G-associated kinase  GAK 
CCR4-NOT transcription complex subunit 8  CNOT8 
Isoform 2 of Adaptin ear-binding coat-associated protein 1  NECAP1 
Double-stranded RNA-binding protein Staufen homolog 2  STAU2 
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Prefoldin subunit 6  PFDN6 
Zinc finger transcription factor Trps1 (Fragment)  TRPS1 
Protein numb homolog (Fragment)  NUMB 
CCR4-NOT transcription complex subunit 6-like (Fragment)  CNOT6L 
Lon protease homolog, mitochondrial  LONP1 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 2  
SMARCD2 
UBX domain-containing protein 7  UBXN7 
F-box/SPRY domain-containing protein 1  FBXO45 
Pre-B-cell leukemia transcription factor 2  PBX2 
Nucleolar and coiled-body phosphoprotein  NOLC1 
Cyclic AMP-dependent transcription factor ATF-6 alpha  ATF6 
 
 
 
B. ONLY Hoxa9 INTERACTING-PROTEINS  
WD repeat-containing protein 6  WDR6 
Translational activator GCN1  GCN1L1 
Pentatricopeptide repeat domain-containing protein 3, mitochondrial  PTCD3 
Casein kinase II subunit alpha'  CSNK2A2 
DNA-directed RNA polymerase II subunit RPB3  POLR2C 
28S ribosomal protein S6, mitochondrial  MRPS6 
Thymidine kinase  TK1 
Isoform 2 of WD repeat-containing protein 47  WDR47 
DDB1- and CUL4-associated factor 10  DCAF10 
Thymidine kinase, cytosolic  TK1 
Anaphase-promoting complex subunit 1  ANAPC1 
Probable cytosolic iron-sulfur protein assembly protein CIAO1  CIAO1 
Ubiquitin-conjugating enzyme E2 O  UBE2O 
Ribonuclease P protein subunit p30  RPP30 
WD repeat domain phosphoinositide-interacting protein 3  WDR45B 
Mitogen-activated protein kinase 1  MAPK1 
Growth factor receptor-bound protein 2  GRB2 
H/ACA ribonucleoprotein complex non-core subunit NAF1  NAF1 
Paraneoplastic antigen Ma2  PNMA2 
28S ribosomal protein S2, mitochondrial  MRPS2 
Myc-associated zinc finger protein (Fragment)  MAZ 
Transmembrane emp24 domain-containing protein 5  TMED5 
Leucine-rich repeat-containing protein 1  LRRC1 
RNA methyltransferase-like protein 1  RNMTL1 
Schlafen family member 11  SLFN11 
Protein SMG5  SMG5 
2-oxoisovalerate dehydrogenase subunit beta, mitochondrial  BCKDHB 
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E3 ubiquitin-protein ligase HERC2  HERC2 
rRNA 2'-O-methyltransferase fibrillarin  FBL 
Nucleolar protein 56  NOP56 
Isochorismatase domain-containing protein 2, mitochondrial (Fragment)  ISOC2 
28S ribosomal protein S24, mitochondrial  MRPS24 
Isoform 3 of FAD synthase  FLAD1 
Probable serine carboxypeptidase CPVL  CPVL 
CDKN2A-interacting protein  CDKN2AIP 
HIG1 domain family member 1A, mitochondrial  HIGD1A 
GTP-binding protein 1  GTPBP1 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A  STT3A 
Tripartite motif-containing protein 26 (Fragment)  TRIM26 
28S ribosomal protein S9, mitochondrial  MRPS9 
Transmembrane emp24 domain-containing protein 1  TMED1 
Interferon-inducible double stranded RNA-dependent protein kinase activator A  PRKRA 
Peptidyl-prolyl cis-trans isomerase-like 4  PPIL4 
Nucleolar complex protein 2 homolog  NOC2L 
Nucleolar MIF4G domain-containing protein 1  NOM1 
Microsomal glutathione S-transferase 3  MGST3 
Isoform 3 of Protein spinster homolog 1  SPNS1 
Lysine-rich nucleolar protein 1 (Fragment)  KNOP1 
Probable ATP-dependent RNA helicase DDX41  DDX41 
Isoform 2 of ATP-dependent RNA helicase DDX54  DDX54 
Isoform 2 of Acidic leucine-rich nuclear phosphoprotein 32 family member B  ANP32B 
ATP-dependent RNA helicase DDX55  DDX55 
RISC-loading complex subunit TARBP2 (Fragment)  TARBP2 
Casein kinase I isoform alpha (Fragment)  CSNK1A1 
Isoform 2 of Replication factor C subunit 5  RFC5 
Serine palmitoyltransferase 1  SPTLC1 
Coatomer subunit gamma-2  COPG2 
Isoform 2 of Histone deacetylase 6  HDAC6 
Isoform 3 of PCI domain-containing protein 2]  PCID2 
Isoform 2 of RNA-binding protein 28  RBM28 
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial (Fragment)  BCKDHA 
Isoform 2 of Anaphase-promoting complex subunit 7  ANAPC7 
Protein FAM91A1  FAM91A1 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  PLOD1 
Serine/threonine-protein kinase A-Raf  ARAF 
28S ribosomal protein S18c, mitochondrial  MRPS18C 
STAGA complex 65 subunit gamma  SUPT7L 
Protein phosphatase 1 regulatory subunit 3D  PPP1R3D 
Mediator of RNA polymerase II transcription subunit 8  MED8 
Isoform C of Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial  IDH3B 
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Protein phosphatase 1F  PPM1F 
General transcription factor 3C polypeptide 5  GTF3C5 
Isoform 2 of ATPase WRNIP1  WRNIP1 
Protein zer-1 homolog  ZER1 
SART3 protein  SART3 
DNA-directed RNA polymerase I subunit RPA2  POLR1B 
Nischarin  NISCH 
Anaphase-promoting complex subunit 10 (Fragment)  ANAPC10 
Mediator of RNA polymerase II transcription subunit 15  MED15 
Syntaxin-17  STX17 
Casein kinase I isoform epsilon  CSNK1E 
Isoform 4 of Interleukin-1 receptor-associated kinase 1  IRAK1 
Ubiquitin carboxyl-terminal hydrolase 10  USP10 
Polynucleotide 5'-hydroxyl-kinase NOL9  NOL9 
Isoform 4 of Elongator complex protein 2  ELP2 
Rab3 GTPase-activating protein non-catalytic subunit  RAB3GAP2 
DNA-directed RNA polymerase II subunit RPB1  POLR2A 
Mediator of RNA polymerase II transcription subunit 14  MED14 
Dehydrogenase/reductase SDR family member 7B (Fragment)  DHRS7B 
Target of rapamycin complex subunit LST8  MLST8 
C-terminal-binding protein 1 (Fragment)  CTBP1 
Acyl-coenzyme A thioesterase 8 (Fragment)  ACOT8 
Isoform 3 of RNA-binding protein Musashi homolog 2  MSI2 
Ferritin  FTH1 
Transcription initiation factor IIA subunit 2  GTF2A2 
Proteasome activator complex subunit 3 (Fragment)  PSME3 
Cell division cycle protein 27 homolog (Fragment)  CDC27 
FKBP8 isoform 1  FKBP8 
Isoform 2 of Ras suppressor protein 1  RSU1 
N-alpha-acetyltransferase 30 (Fragment)  NAA30 
Isoform 3 of 28S ribosomal protein S11, mitochondrial  MRPS11 
BRCA1-A complex subunit RAP80 (Fragment)  UIMC1 
Cysteine desulfurase, mitochondrial (Fragment)  NFS1 
E3 ubiquitin-protein ligase TRIM32 (Fragment)  TRIM32 
Myelin expression factor 2 (Fragment)  MYEF2 
Inositol polyphosphate 5-phosphatase K (Fragment)  INPP5K 
Isoform 2 of TBC1 domain family member 10B  TBC1D10B 
Isoform 2 of Zinc finger CCHC domain-containing protein 10  ZCCHC10 
Striatin-4 (Fragment)  STRN4 
Zinc finger protein 658B  ZNF658B 
60S ribosomal protein L7-like 1  RPL7L1 
Nuclear pore complex protein Nup205  NUP205 
AP-3 complex subunit beta-2 (Fragment  AP3B2 
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mRNA turnover protein 4 homolog  MRTO4 
Alpha-2-macroglobulin receptor-associated protein  LRPAP1 
Protein FAM203B  FAM203B 
ATPase family AAA domain-containing protein 1  ATAD1 
Isoform 2 of 28S ribosomal protein S5, mitochondrial  MRPS5 
Protein THEM6  THEM6 
Isoform 2 of Probable ATP-dependent RNA helicase DDX47  DDX47 
Copine-1  CPNE1 
Protein CMSS1 (Fragment)  CMSS1 
Mannose-1-phosphate guanyltransferase beta  GMPPB 
Four and a half LIM domains protein 3  FHL3 
Copine-3  CPNE3 
Mannose-1-phosphate guanyltransferase alpha  GMPPA 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  SDHB 
Sorting and assembly machinery component 50 homolog  SAMM50 
S1 RNA-binding domain-containing protein 1  SRBD1 
Isoform 2 of Transcription elongation factor SPT5  SUPT5H 
Lysophosphatidylcholine acyltransferase 1  LPCAT1 
Leucine-rich repeat-containing G-protein-coupled receptor 6 (Fragment)  LGR6 
E3 ubiquitin-protein ligase TRIM56  TRIM56 
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  NDUFV1 
Isoform 2 of Interferon-induced, double-stranded RNA-activated protein  EIF2AK2 
WD repeat-containing protein 75  WDR75 
Fanconi anemia group I protein  FANCI 
Tetratricopeptide repeat protein 27  TTC27 
Leucine-rich repeat-containing protein 47  LRRC47 
Isoform 2 of Pre-mRNA-processing factor 6  PRPF6 
E3 ubiquitin-protein ligase HECTD3  HECTD3 
Genetic suppressor element 1 (Fragment)  GSE1 
Intraflagellar transport protein 81 homolog (Fragment)  IFT81 
Ubiquitin-protein ligase E3C  UBE3C 
Isoform 3 of Ribonuclease 3  DROSHA 
Helicase SKI2W  SKIV2L 
Isoform 3 of Protein VPRBP  VPRBP 
Isoform 2 of Nucleoporin NUP188 homolog  NUP188 
Mediator of RNA polymerase II transcription subunit 1  MED1 
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C. ONLY Nup98 INTERACTING-PROTEINS 
MOB kinase activator 2  MOB2 
Cold-inducible RNA-binding protein  CIRBP 
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2  ACAP2 
Isoform 3 of CAP-Gly domain-containing linker protein 1  CLIP1 
Crk-like protein  CRKL 
Survival of motor neuron-related-splicing factor 30  SMNDC1 
Isoform B of Peptidyl-prolyl cis-trans isomerase E  PPIE 
Bystin  BYSL 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial  
DLAT 
Methylcytosine dioxygenase TET2  TET2 
Eukaryotic translation initiation factor 1A, Y-chromosomal  EIF1AY 
Isoform 3 of Dynactin subunit 3  DCTN3 
WD repeat-containing protein 5  WDR5 
Succinate-semialdehyde dehydrogenase, mitochondrial  ALDH5A1 
Peptidyl-prolyl cis-trans isomerase B  PPIB 
Splicing regulatory glutamine/lysine-rich protein 1  SREK1 
Isoform 4 of Dedicator of cytokinesis protein 7  DOCK7 
Sjoegren syndrome/scleroderma autoantigen 1  SSSCA1 
Peptidyl-prolyl cis-trans isomerase H (Fragment)  PPIH 
Isoform 2 of PEST proteolytic signal-containing nuclear protein  PCNP 
Isoform 4 of RNA-binding protein 42  RBM42 
Actin-related protein T1  ACTRT1 
La-related protein 7 (Fragment)  LARP7 
Isoform 2 of Proteasome subunit alpha type-7  PSMA7 
Actin-related protein 2/3 complex subunit 5  ARPC5 
Guanine nucleotide exchange factor for Rab-3A (Fragment)  RAB3IL1 
H/ACA ribonucleoprotein complex subunit 4  DKC1 
Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1  BAIAP2L1 
Anoctamin-5  ANO5 
U7 snRNA-associated Sm-like protein LSm10  LSM10 
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1  NUCKS1 
Thioredoxin-dependent peroxide reductase, mitochondrial  PRDX3 
60S ribosomal export protein NMD3  NMD3 
SAP30-binding protein (Fragment)  SAP30BP 
Tubulin--tyrosine ligase-like protein 12  TTLL12 
Peroxisomal targeting signal 1 receptor (Fragment)  PEX5 
Protein LYRIC  MTDH 
Mammalian ependymin-related protein 1  EPDR1 
Glutaredoxin-3  GLRX3 
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16  DHX38 
Isoform Short of Tight junction protein ZO-1  TJP1 
Rho guanine nucleotide exchange factor 10 (Fragment)  ARHGEF10 
Isoform 2 of Pre-mRNA-processing factor 40 homolog A  PRPF40A 
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D. COMMON HOXA9 and NUP98-HOXA9 INTERACTING PROTEINS  
Insulin-degrading enzyme  IDE 
Casein kinase II subunit alpha  CSNK2A1 
Isoform 7 of Protein LAP2  ERBB2IP 
Transcription factor A, mitochondrial  TFAM 
Mitogen-activated protein kinase kinase kinase kinase 4  MAP4K4 
Protein RMD5 homolog A  RMND5A 
Ribosome biogenesis protein BOP1  BOP1 
Isoform 4 of Transcription factor Sp3  SP3 
COP9 signalosome complex subunit 7a  COPS7A 
Homeobox protein Hox-A9  HOXA9 
COP9 signalosome complex subunit 4  COPS4 
Isoform 2 of Glycogen [starch] synthase, muscle  GYS1 
COP9 signalosome complex subunit 6  COPS6 
COP9 signalosome complex subunit 2  COPS2 
COP9 signalosome complex subunit 5  COPS5 
COP9 signalosome complex subunit 1  GPS1 
Isoform 2 of Armadillo repeat-containing protein 8  ARMC8 
Replication protein A 32 kDa subunit  RPA2 
Putative adenosylhomocysteinase 2  AHCYL1 
NAD-dependent protein deacetylase sirtuin-1  SIRT1 
E3 ubiquitin-protein ligase ARIH1  ARIH1 
COP9 signalosome complex subunit 8  COPS8 
Isoform 3 of Serine protease HTRA2, mitochondrial  HTRA2 
Isoform 2 of Putative adenosylhomocysteinase 3  AHCYL2 
Protein FAM98A  FAM98A 
Isoform 2 of Uncharacterized protein C18orf25  C18orf25 
Replication protein A 14 kDa subunit  RPA3 
Homeobox protein Hox-D9  HOXD9 
Muskelin  MKLN1 
Importin subunit alpha-3  KPNA3 
Isoform GN-1 of Glycogenin-1  GYG1 
Cleavage and polyadenylation-specificity factor subunit 7 (Fragment)  CPSF7 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A member 5  SMARCA5 
Molybdopterin molybdenumtransferase  GPHN 
RNA-binding protein 27  RBM27 
Intraflagellar transport protein 46 homolog (Fragment)  IFT46 
Mov10, Moloney leukemia virus 10, homolog (Mouse), isoform CRA_a  MOV10 
Macrophage erythroblast attacher  MAEA 
Isoform 2 of COP9 signalosome complex subunit 7b  COPS7B 
Structural maintenance of chromosomes protein 3  SMC3 
High mobility group protein HMG-I/HMG-Y  HMGA1 
E3 ubiquitin-protein ligase RAD18  RAD18 
E3 ubiquitin-protein ligase ARIH2  ARIH2 
Isoform 4 of Nucleolar and spindle-associated protein 1  NUSAP1 
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Isoform HMG-Y of High mobility group protein HMG-I/HMG-Y  HMGA1 
Isoform 6 of Cyclin-dependent kinase inhibitor 2A, isoform 4  CDKN2A 
Phosphorylated adapter RNA export protein  PHAX 
Vacuolar protein sorting-associated protein 18 homolog  VPS18 
Glucose-induced degradation protein 4 homolog  GID4 
Dr1-associated corepressor (Fragment)  DRAP1 
 
 
 
E. COMMON NUP98 and NUP98-HOXA9 INTERACTING PROTEINS  
Isoform 2 of UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 
110 kDa subunit  
OGT 
Splicing factor, suppressor of white-apricot homolog  SFSWAP 
Prefoldin subunit 5 (Fragment)  PFDN5 
Pinin  PNN 
  
  
  
  
F. COMMON HOXA9, NUP98 and NUP98-HOXA9 INTERACTING PROTEINS  
Ran-binding protein 10  RANBP10 
Histone deacetylase  HDAC2 
Histone deacetylase 1  HDAC1 
Exosome complex component CSL4  EXOSC1 
Transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B), isoform 
CRA_b  TCEB2 
 
 
 
 
 
 
 
 
 
 
133 
 
  
  
  
  
  
  
 APPENDIX II 
 
 
 
 Publications 
 Oral communications and posters of the meetings attended 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
134 
 
 
  
135 
 
PUBLICATIONS 
1. Ana Rio-Machin, Gonzalo Gomez-Lopez, Alba Maiques-Diaz, Maureen A. Powers, Sara Alvarez, 
Rocio N Salgado, Claudia Haferlach, Maria Jose Larrayoz, Maria Jose Calasanz and Juan C. Cigudosa. 
New insights into the contribution of the two moieties of NUP98-HOXA9 provide a wider window of 
targeted therapy in acute myeloid leukemia. Oct 2014. Submitted to Blood. 
 
2. Ana Rio-Machin, Javier Muñoz, Fernando Garcia-Martinez, Maureen A. Powers and Juan C. 
Cigudosa. The oncogene NUP98-HOXA9, more than a leukemic transcription factor. Oct 2014. 
Submitted to Haematologica. 
 
3. Alba Maiques-Diaz, Alvaro Eguileor, Mahesh Shestha, Gonzalo Gómez López, Mark Wunderlich, 
Ana Rio-Machin, Xavier Agirre , James C. Mulloy, Juan C. Cigudosa and Sara Alvarez. Aberrant 
chromatin acetylation in MLL-AF9 leukemia mediates the response to HDAC inhibition. Sep 2014. 
Submitted to Plos One. 
 
4. Rocío N Salgado, Ana Rio-Machin, Juliane Menezes, C Guillén, J Sánchez-Calero, A Sánchez-López, 
F García-Sánchez, Sara Álvarez and Juan C Cigudosa. GTF2I/RARA fusion gene: a novel RARA 
rearrangement in a variant acute promyelocytic leukemia resistent to ATRA (in preparation). 
 
5. Alberto Cascon, Iñaki Comino-Méndez, María Currás-Freixes, Aguirre De Cubas, Laura Contreras, 
Susan Richter, Veronika Mancikova, Andrés Pérez-Barrios, María Calatayud, Sharona Azriel, Rosa 
Villar-Vicente, Javier Aller, Fernando Setién, Juan Garcia, Ana Rio-Machin, Rocío Letón, Álvaro 
Gómez-Graña, Lucia Inglada-Pérez, María Apellániz-Ruiz, Giovanna Roncador, Manel Esteller, Cristina 
Rodríguez-Antona, Jorgina Satrústegui, Graeme Eisenhofer, Miguel Urioste, and Mercedes Robledo. 
Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. Oct 2014. 
Provisionally accepted to JNCI. (IF: 15.161) 
 
6. Ana Rio-Machin, Bibiana Ferreira, Travis Henry, Gonzalo Gómez-López, Xabier Agirre, Sara 
Alvarez, Sandra Rodriguez-Perales, Felipe Prosper, M José Calasanz, Joaquín Martínez, Rafael 
Fonseca, and Juan C. Cigudosa. The downregulation of specific miRNAs in hyperdiploid multiple 
myeloma mimics the effect of the most frequent IgH translocations observed in the non-hyperdiploid 
subtype. Leukemia. 2013 Apr;27(4):925-31 (IF: 10.164) 
 
7. Ana Rio-Machin, Juliane Menezes, Agirre X, Ferreira BI, Acquadro F, Rodriguez-Perales 
S, Arribalzaga Juaristi K, Alvarez S, Cigudosa JC. Abrogation of RUNX1 gene expression in de novo 
myelodysplastic syndrome with t(4;21)(q21;q22). Haematologica. 2012 Apr;97(4):534-7 (IF: 6.424) 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
